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Summary 
Effective treatment of malignant gliomas remains one of the great challenges in 
neurooncology. The incidence of malignant gliomas is 5 to 10 per 100.000 persons, 
and the outcome is always fatal with a mean survival of less than one year. Tumor 
location and invasiveness into normal brain tissues are the two main obstacles for 
surgical cure. Resistance to conventional chemo- and radiotherapy is a consequence 
of high genetic instability leading to countless mutations. The presence of the blood-
brain barrier makes drug targeting difficult. Nevertheless, mechanisms of 
gliomagenesis are becoming better understood. Among the key cellular pathways, 
those controlling apoptosis, proliferation, repair and invasion are most frequently 
disrupted due to alterations in TP53, p16/p14, RB, PTEN, EGFR and PDGFR. In 
addition, many regulatory genes are epigenetically silenced by methylation and 
acetylation. A cardinal feature of malignant gliomas, as well as many other cancers, is 
a high rate of ATP consumption via upregulation of glycolysis. All these pathways 
represent potential targets for interference with specific drugs.  
Recently, small lipo-soluble molecules were designed as a new class of drugs more 
specifically targeting those altered cancer pathways. These drugs were applied to 
human GBM cells for induction of apoptosis as a readout of drug efficacy. Single 
applications of the PKIs, AEE788, Glivec and RADOO1 or the glycolytic inhibitor, 
2-DG, were not able to induce cell death, but only a cytostatic effect at clinically 
meaningful dose ranges. In contrast, cytotoxic drugs like the microtubule inhibitor 
EPO906 or HDAC inhibitors (HDIs) like trichostatin A, sodium butyrate and 
LAQ824 were able to efficiently trigger apoptosis, but are known to lead to toxicity 
with increased dose ranges in mice and humans. We therefore tested combinations of 
low doses of cytotoxic drugs with cytostatic drugs and indomethacin. Since p21 was 
shown to be re-expressed upon HDIs and to protect cancer cells against apoptotic 
stimuli, 2-DG was used as a sensitizer for HDIs-induced apoptosis. 2-DG strongly 
inhibits protein expression. Synergistic induction of apoptosis was observed in glioma 
and other cancer cell lines upon this combined treatment. Thus, drug combination that 
inflict a cytotoxic stress to cancer cells and simultaneously impair the p21-regulated 
response of the stressed cells to halt the cell cycle machinery may be a new way to 
treat cancer in the future.  
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Therapeutic resistance of GBMs. Cancer remains the second most fatal disorder in 
developed countries after cardiovascular disease. In France, an increase of 60% of 
cancer cases was noticed over the last twenty years. Among all cancers, glioblastoma 
multiforme (GBM) is the most frequent and malignant human brain tumor. GBMs are 
very aggressive, highly invasive and neurologically destructive and are considered to 
be among the deadliest of human cancers, with median survival ranging from 9 to 12 
months. For example, from the 715 newly diagnosed cases of glioblastoma that 
occurred in the resident population of the Canton of Zurich in Switzerland between 
1980 and 1994, 42.4% died at 6 months, 17.7% at 1 year, and 3.3% at 2 years 
(Ohgaki, Dessen et al. 2004). Importantly, these statistics have not changed 
significantly over the past two decades, despite treatment efforts underlined by 
technological advances in neurosurgery, radiation therapy and drug development. 
This is in part a consequence of the location of these tumors in relatively inaccessible 
tissues, harboring critical neurological functions, and of the presence of the blood-
brain barrier which is a major obstacle for drug treatment. Since twenty years, the 
explosion of knowledge in cancer biology, basic science and drug development has 
lead to efficient progress in the treatment of a number of common human cancers, 
including those of breast, lung or prostate. However, these therapies are ineffective in 
the treatment of GBMs. By now, human malignant gliomas are well characterized, 
demonstrated by the creation of several murine glioma models, but in these models 
only one or two pathways are targeted whereas in human gliomas, many additional 
genes and pathways are altered to promote the development of the tumor (Merlo 
2003). 
 
History of brain tumor surgery. The history of treating brain tumors dates from the 
middle of the 19th century and parallels advances in modern surgical techniques. 
Cranial surgery, however, is much older, although the underlying diseases remain 
speculative. A fascinating archaeological discovery was made in 1997, near 
Ensisheim (Alsace), which gives evidence for stone-age cranial surgery. The skull of 
a man showed a double trepanation practiced 7000 years ago (Alt, Jeunesse et al. 
1997). The case described in Nature review “is exceptional for several reasons: it 
appears to be the oldest healed neurosurgical operation known worldwide, its 
technical realization testifies to the high craftsmanship and well-founded anatomical 
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knowledge of the surgeon, and the success of the unusual trepanations is established 
by the long survival of the “patient.” The first modern brain tumor surgery was 
performed in 1884 by Rickman Godlee, but, because of technical difficulties, the 
initial enthusiasm for surgery soon dropped. Surgical techniques improved with 
Harvey Cushing in 1926 where the first histological grading of tumors was developed 
and showed a correlation with the clinical outcome. Radiation therapy was introduced 
soon thereafter, but the median survival was only increased for several months. In the 
eighties, chemotherapy was developed for leukemia and solid tumors, and agents that 
could pass the blood-brain barrier were added to the treatment protocols for brain 
tumors. Nitrosourea-based chemotherapy could increase median survival in 
combination with surgery and radiotherapy for a few weeks, but patients cannot be 
cured with any cytotoxic agent currently available. Recently, radio-chemotherapy has 
prolonged mean survival from 12 to 14 months in younger GBM patients with a good 
performance score and also increased the rate of patients surviving 24 months - a 
modest effect with regard to costs and effort (Stupp, Mason et al. 2005). Progress in 
molecular and cellular biology will eventually lead to a better understanding of the 
biology of human gliomas which will permit the development of more specific and 
effective therapies (Maher, Furnari et al. 2001). 
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1.  Central nervous system (CNS) development and cellular 
origin of gliomas 
 
 
 1.1. Precursors of CNS tumors 
 
 
In vertebrates, two types of progenitor cells arise from the embryonic neural tube 
(neuroectoderm): neuronal-restricted progenitor cells and glial-restricted progenitor 
cells, for the basis of all cell types of the central nervous system (CNS), including 
neurons, astrocytes and oligodendrocytes. Astrocytes perform diverse functions in the 
CNS, including regulation of neuronal growth and survival, guiding cell migration 
and axonal growth during development, promoting synapse formation and modulating 
synaptic transmission, and orchestrating inflammatory and immune responses during 
brain injury and infection (Maher, Furnari et al. 2001; Wechsler-Reya and Scott 2001; 
Zhu and Parada 2002). 
 
At the end of the development, neurons become post-mitotic and only a smaller 
fraction of stem cells remain, whereas glial cells retain the ability to proliferate 
throughout life. It is therefore not surprising that most CNS tumors are of glial origin. 
These tumors are called gliomas, and include tumors composed predominantly of 
astrocytes (astrocytomas), oligodendrocytes (oligodendroglioma) or a mixture of 
various glial cells (oligoastrocytomas) (Annex 1) 
 
 
1.2. Grading and classification of gliomas 
 
 
The World Health Organization (WHO) grading system classifies gliomas into grade 
I to IV based on their degree of malignancy, as determined by histopathological 
criteria. In the CNS, grade I gliomas generally develop in a benign way and are 
circumscribed, whereas grade II-IV gliomas are malignant and diffusely infiltrate 
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throughout the brain. Astrocytoma are the most common CNS neoplasm, representing 
more than 60% of all primary brain tumors. Glioblastoma multiforme (GBM) is the 
most malignant form of infiltrating astrocytoma (WHO grade IV astrocytoma) and 
one of the most aggressive human cancers, with a very short median survival of 8 to 
10 months. 
Grade IV astrocytoma can be divided into two subclasses based on clinical 
characteristics: primary and secondary GBMs. Primary GBMs, present in older 
patients, are very aggressive, highly invasive and arise from a de novo process, in the 
absence of a pre-existing low-grade lesion. Secondary GBMs are usually observed in 
younger patients and develop progressively from low-grade astrocytoma over a period 
of 5 to 10 years. Genetic studies of GBM indicate that there are common, but also 
distinct genetic pathways that lead to these two subtypes (Maher, Furnari et al. 2001; 
Wechsler-Reya and Scott 2001; Zhu and Parada 2002) (Annex 1). 
 
 
1.3. Genetic alterations at the origin of gliomas 
 
 
The median survival from the time that a GBM is established is statistically the same 
for primary and secondary GBM, which reflects equal capacities to proliferate, invade 
and resist to all therapeutic modalities. The same genetic pathways are targeted in 
both sub-types, but the frequency of specific genetic mutations may differ in the two 
GBMs types. Microvascular proliferation and necrosis are found in primary as well as 
in secondary GBM, and both are composed of highly infiltrative and less well-
differentiated cells than low-grade astrocytomas. It has been proposed that in 
secondary GBM, astrocytic tumor cells in low-grade gliomas undergo 
dedifferentiation during progression to GBM, possibly because of the accumulation of 
genetic mutations in key pathways regulating glial cell differentiation. A similar 
mechanism occurs in primary GBM, or as an alternative, primary GBM represents 
malignant transformation of more immature glial precursor cells, such as the 
pluripotent neural stem cells or the glial progenitor cells (Maher, Furnari et al. 2001; 
Wechsler-Reya and Scott 2001; Zhu and Parada 2002). 
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1.3.1. Secondary GBM 
 
The presence of some genetic alterations in both low and high-grade astrocytomas 
indicate that these common mutations are involved in early phases of tumor 
formation. For example, the tumor suppressor protein p53, which regulates cell cycle 
progression and apoptosis, fits to this hypothesis. Indeed, patients with Li-Fraumeni 
syndrome carry a germ line mutation in the TP53 gene (which encodes p53 in 
humans) and are predisposed to the development of various tumors, including 
astrocytomas. Mutations occurring in the course of gliomagenesis are found with the 
same frequency in all grades of astrocytomas (more than 60% for p53). The early 
occurrence of TP53 mutation point to the need for astrocytoma cells to evade 
apoptosis in order to migrate and survive in a non-adequate environment. Although 
the study of human astrocytomas shows an association of TP53 mutations with early 
tumor stages, observations in knock out or transgenic mice indicate that the loss of 
TP53 alone is not sufficient to initiate astrocytoma formation, and that additional 
genetic events are required (Maher, Furnari et al. 2001; Wechsler-Reya and Scott 
2001; Zhu and Parada 2002). 
Downstream of the growth factor receptors are two major pathways, the Ras and the 
PI3K/PTEN pathways The small GTP-binding protein, Ras, is an important 
downsteam effector of the growth factor receptor tyrosine kinases (GF-RTK), 
involved in transmission of survival and growth signals. The GF-RTK-RAS signaling 
cascade is frequently targeted in human cancers rendering cancer cells independent of 
exogenous growth factors (Kinzler and Vogelstein 1996). Among them, platelet-
derived growth-factor PDGF and its receptor are both highly co-expressed in every 
grade of astrocytomas, indicating that the cells establish an autocrine stimulatory 
loop. Neurofibromatosis type 1 (NF-1) is a familial cancer syndrome in which 
patients develop multiple tumors of the CNS. The gene NF1 encodes for a protein that 
shares homology with the GAP family (RAS GTPase-activating protein). Loss of both 
NF1 copies has been shown in these tumors, negatively regulating Ras. Activation of 
the RAS-mediated MAPK is found in astrocytomas. Transgenic mice models 
overexpressing oncogenic Ras in astrocytes lead to development of astrocytoma. 
Concerning the PI3K/PTEN pathway, mutations in the PI3KCA gene have also been 
detected in glioblastomas and other forms of brain tumors. These mutations lead to 
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increased lipid kinase activity (Samuels, Wang et al. 2004). In addition, the 
suppressor tumor gene PTEN is mutated or deleted in more than 30% of primary 
GBMs. These mutations lead to increased AKT activity, promoting growth and 
survival (Knobbe, Merlo et al. 2002). These observations support the hypothesis that 
p53 and the growth factor signaling pathways are involved in the initiation of low-
grade astrocytoma development.  
 
Tumor progression is caused by additional genetic alterations of genes involved in the 
regulation of cell cycle progression that lead to uncontrolled proliferation and high 
mitotic activity, the hallmark of high-grade astrocytomas (Ishii, Maier et al. 1999). 
The tumor suppressor gene Rb is the key regulator of the G1/S-phase checkpoint. RB 
is regulated by cyclin-dependent kinases (CDK) and CDK inhibitors (CKI) which are 
frequently mutated in GBM: loss of p16INK4A and p14ARF (both are encoded by the 
same gene, CDKN2A, but use an alternative reading frame) is detected in 40 to 57% 
of GBMs, CDK4 amplification and loss of RB are identified in 14 to 33% of GBMs. 
In total, 80% of GBMs harbour mutations in the INK4A/CDK4/RB pathway, whereas 
such mutations are rare in low-grade astrocytomas (Labuhn, Jones et al. 2001). The 
remaining 20% GBMs show mutations in other players of this pathway, such as the 
overexpression of Cyclin D1 and CDK6. Studies in mouse models support the idea 
that all these mutations are important for the progression of astrocytomas, but not for 
tumor initiation (Maher, Furnari et al. 2001; Wechsler-Reya and Scott 2001; Zhu and 
Parada 2002) (Annex 1, 2). 
 
1.3.2. Primary GBM 
 
Primary GBM arise rapidly, within less than 3 months, without evidence of a pre-
existing low-grade lesion. However, the analysis of mutations indicates that the same 
genetic pathways are affected in both primary and secondary GBMs, namely p53, the 
growth factor pathway and the cell cycle regulatory pathway. In primary GBMs, both 
p53 and RB pathways are simultaneously affected by the homologous deletion of the 
CDKN2A locus, which encodes for p16INK4A (involved in RB regulation) and p14ARF. 
ARF stabilizes p53 by antagonizing MDM2 (mouse double minute 2) which targets 
p53 for ubiquitin-mediated degradation. The amplification of the epidermal growth 
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factor receptor (EGFR) gene, which promotes growth of the tumor, is found in 40% 
of primary GBMs, but is rare in secondary GBMs. The loss of the long arm of 
chromosome 10 is the most common genetic alteration associated with GBMs. 
Several genes are located in this region, including the tumor suppressor PTEN which 
is deleted or mutated in more than 30% of primary GBMs, and only in 4% of 
secondary GBMs. The PTEN protein functions as a protein and lipid phosphatase for 
which the main substrate is the phosphatidylinositol(3,4,5)-triphosphate (PIP3), a 
PI3K product. PI3K has been found to be mutated in GBMs (Samuels, Wang et al. 
2004). PTEN acts as a negative regulator of the PI3K-AKT survival pathway since 
AKT activity is enhanced in PTEN mutated/deleted GBMs , promoting growth and 
cell survival (Vivanco and Sawyers 2002; Zhu and Parada 2002; Sansal and Sellers 
2004). The carboxyl-terminal modulator protein (CTMP) is another negative 
regulatory component of the pathway controlling PKB activity (Maira, Galetic et al. 
2001). The gene coding CTMP has been found to be epigenetically silenced in GBMs 
(Knobbe, Reifenberger et al. 2004). 
Recent observations support a plastic model in which development of primary GBMs 
can arise in two ways: primary GBM can develop from transformation of adult neural 
stem cells localized in the subventricular zones of the brain or can dedifferentiate 
from astrocytes. Glial progenitor cells can develop into neural stem cells in response 
to exogenous fibroblast growth factor 2 (FGF2), astrocytes can be de-differentiated 
into neural stem cells in response to epidermal growth factor (EGF) signaling and the 
loss of INK4A/ARF. Thereafter, amplification of the EGFR or mutations in PTEN 
can lead to primary GBM (Maher, Furnari et al. 2001; Wechsler-Reya and Scott 
2001; Zhu and Parada 2002) (Annex 1, 2). 
 
 
 
2. General tumor biology and specific aspects for GBMs  
 
 
2.1. Suppression of the natural induction of apoptosis  
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The increase of a tumor mass arise through the loss of the equilibrium between 
cellular proliferation and cell death. The apoptotic index correlates with tumor 
proliferation and is negatively associated with survival. Tumor cell proliferation is 
associated with loss of normal induction of apoptosis. In normal cells, DNA damage, 
induced by irradiation, drugs or environmental toxic agents, induces cell death. One 
key sensor of DNA damage is the nuclear protein TP53 (Vogelstein, Lane et al. 
2000). This transcription factor and tumor suppressor integrates numerous signals that 
are crucial for the control of life and death of the cell (Lane and Fischer 2004; Levine, 
Finlay et al. 2004). The protein p53 is activated, in part, by various signals that induce 
its dissociation from its inhibitor, MDM2. Indeed, p53 is phosphorylated by various 
kinases in response to DNA-damaging stimuli. Once activated, p53 binds to specific 
sequences in the DNA and initiates the transcription of many genes involved in 
genetic stability, cell-cycle inhibition and apoptosis. Concerning the cell cycle 
inhibition, p53 induces or maintains growth arrest through increased expression of 
cell-cycle regulators, such as p21, an inhibitor of Cyclin Dependent Kinases (CDK), 
allowing repair of DNA damage (el-Deiry, Tokino et al. 1993; Harper, Adami et al. 
1993). Mutated cells are normally eliminated by apoptosis. However, if mutations 
generate relative resistance to apoptosis, such as mutations in p53 or HDM2 genes, 
the cell-intrinsic threshold to induce apoptosis is considerably elevated (Van Meir, 
Roemer et al. 1995). Consecutive tumor cell populations are selected due to mutations 
that convey a growth advantage. This clonal evolution of cancer is the Darwinian 
principle for tumorigenesis (Nowell 1976). In most cases, the loss of p53 function and 
activation of AKT (by mutation or deletion in the PTEN gene or PI3K encoding gene) 
occurring in GBMs contribute to the suppression of apoptosis in the presence of 
apoptotic stimuli and to an increased proliferation (Vivanco and Sawyers 2002). 
Mutations/deletions in TPp53 gene occur with a frequency of 75% in human 
glioblastoma cell lines (Ishii, Maier et al. 1999). Studies done in GBM patients show 
that the mutations in the p53 gene do not markedly affect the survival of GBM 
patients, but suggest that in gliomas, the p53 mutation may contribute not only to 
tumorigenesis (as an early event) but also to progression to malignancy (as a late 
event) (Shiraishi, Tada et al. 2002). 
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2.2 . Uncontrolled proliferation 
 
 
Normal cells are not able to proliferate in the absence of stimulatory signals whereas 
tumor cells generate their own growth signals, which reduce their dependence on the 
stimulation from the surrounding normal tissue. Many known oncogenes act by 
mimicking normal growth signaling and many cancer cells acquire the ability to 
synthesize growth factors to which they are responsive, creating a positive feedback 
loop, either by autocrine or paracrine stimulation. Two illustrative examples are the 
production of the platelet-derived growth factor (PDGF) and transforming growth 
factor (TGFβ) by glioblastomas (Fontana, Bodmer et al. 1991; Lokker, Sullivan et al. 
2002). In addition, growth factor receptors, which often carry tyrosine kinase activity, 
are overexpressed in many cancers, including glioblastomas that overexpress the 
epidermal growth factor receptor (EGFR) (Barker, Simmons et al. 2001). Other 
alterations may elicit ligand-independent signaling. For example, the truncated 
version of EGFR lacks part of its cytoplasmic domain, resulting in a constitutivly 
active receptor and activation of the PI3K/AKT (Vivanco and Sawyers 2002) and the 
MAPK pathways (Hunter 2000). More downstream, other components in the 
signaling pathways can be mutated. Cell cycle regulatory proteins are often disrupted 
in order to allow proliferation and avoid the block at the G1 checkpoint (Molinari 
2000; Kastan and Bartek 2004). Disruption of the cell cycle machinery also 
contributes to glioblastoma development. Changes in the genes encoding cyclins, 
CDKs, CDKs inhibitors (Hunter and Pines 1994; MacLachlan, Sang et al. 1995; 
Fischer and Gianella-Borradori 2003), and the retinoblastoma protein (RB) (Knudson, 
Hethcote et al. 1975) have been observed at high frequency in glioblastomas. RB is 
regulating the progression through G1 by sequestrating the E2F transcription factor 
responsible for the transcription of proteins needed for the transition in S phase and 
the replication (Hanahan and Weinberg 2000). Historically, the RB gene gave rise to 
the concept of the two-step model to inactivate a tumor suppressor gene (Knudson 
1996) by loss of heterozygosity to inactivate the wild-type allele (Cavenee, Scrable et 
al. 1991) . 
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2.3  Sustained angiogenesis 
 
 
Oxygen and nutrients supplied by the vasculature are crucial for cell function and 
survival. Angiogenesis, the formation of new blood vessels, is a discrete step in tumor 
progression that is required for expansion of tumor mass (Bouck, Stellmach et al. 
1996; Hanahan and Folkman 1996). Astrocytomas are strongly oxygen-dependent. 
When grade III astrocytomas progress to grade IV, they show features of hypoxic and 
necrotic palisades (Blouw, Song et al. 2003). The resulting hypoxia is promoting 
formation of new blood vessels that supply the tumor with necessary metabolites. The 
hypoxic response is triggered to a large extent by the hypoxia inducible factor-1 (HIF-
1) (Semenza 2003). HIF-1 is overexpressed in human glioblastomas. Among the most 
prominent target genes of HIF-1 is the angiogenic factor, vascular endothelial growth 
factor (VEGF), which is expressed in the perinecrotic palisading cells (Folkman 
1996). VEGF is also produced by tumor-associated cells like endothelial cells and 
macrophages, as well as by surrounding stromal cells and regulates endothelial cell 
proliferation and vascular permeability. The earliest stages are defined by 
vasodilatation and an increased vascular permeability of pre-existing capillaries or 
post-capillary venules in response to VEGF. The vascular basement membrane and 
the extracellular matrix are locally degraded to allow underlying endothelial cells to 
migrate into the perivascular space and multiply.  
Astrocytic tumor cells do not require neovascularization. They acquire their nutrients 
by co-opting existing blood vessels without initiating angiogenesis, but by growing 
along blood vessels of the vascular-rich brain parenchyma (Brat and Van Meir 2004). 
However, when they progress into glioblastomas, they become hypoxic and necrotic, 
partially due to vessel regression and increased tumor cell proliferation. This initiates 
hypoxia-induced angiogenesis. As soon as these tumors are re-vascularized, they 
become extremely aggressive. Expression of tenascin-C, an extracellular matrix 
glycoprotein, has been found in the wall of the blood vessels and in the ECM of 
GBMs (Chiquet-Ehrismann, Mackie et al. 1986), suggesting a role for this protein in 
angiogenesis (Zagzag, Friedlander et al. 1995) (Annex 3). 
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2.4     Unchecked migratory and infiltration capacities  
 
 
The ability of glioma cells to widely invade normal brain tissue is a key property of 
the malignant gliomas. Malignant lesions are usually considered to be metastatic; 
however, brain tumors differ from these by the fact that they rarely spread to sites 
outside of the CNS (Maher, Furnari et al. 2001; Merlo 2003). The progression is a 
diffuse, locally invasive growth into the normal brain coupled with an increase in 
tumor volume. Moreover, tumors may spread along blood vessels, white matter tracts 
and grey–white matter interfaces. 
Invasion does not correlate with the grade, since low-grade astrocytomas already 
extensively invade throughout normal brain tissue. In the adult CNS, neurons, 
astrocytes and oligodendrocytes are fixed in position and do not migrate. A number of 
studies indicate that PTEN can regulate cell shape and movement (Merlo and Bettler 
2004). In addition, the focal adhesion kinase (FAK) mediates signal transduction by 
integrins and by regulating cell adhesion and migration. Interestingly, FAK is 
overexpressed in primary GBMs (Jones, Machado et al. 2001). Overexpression of 
PTEN inhibits cell spreading and cell migration induced by integrins, whereas 
reduction of PTEN levels has the opposite effect (Maier, Jones et al. 1999). The 
inhibitory effects of PTEN can be blocked by the overexpression of FAK, which 
induces extensive reorganization of the actin cytoskeleton, formation of focal 
adhesions and directional migration (Jones, Machado et al. 2001). Thus, cells lacking 
functional PTEN would be expected to manifest increased migration and increased 
tendency to undergo metastasis. PTEN mutations are found in glioblastomas but 
rarely in low-grade astrocytic tumors (Knobbe, Merlo et al. 2002; Sansal and Sellers 
2004). 
 
 
2.5 . Benefit of bad telomeres 
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Cells which derive from normal tissues are limited to a number of cell divisions 
named the “Hayflick limit” (Hayflick 1997). Telomeres are the protective ends of the 
chromosomes formed by repetitive nucleotide sequences and associated protein 
complexes that are shortened at each cell division. The telomerase lengthens 
telomeres by using an RNA template and is in adults only expressed in stem cells, and 
becomes reactivated in many cancers cells including malignant gliomas. Without 
telomerase, each chromosome looses a few telomere repeats every time it is 
duplicated. This makes the chromosomes unstable, and may lead to genomic 
instability. The integrity of the genome in normal cells is mediated by p53. A 
signaling circuit centered on p53 detects DNA damage and limits the emergence of 
cells with a mutant genome, either by arresting the cell cycle to allow DNA repair or 
by inducing cell death (Artandi, Chang et al. 2000). Since telomerase is reexpressed, 
cancer and immortalized cells have the ability to go indefinitely through cycles of 
chromosome replication followed by cell division (Hanahan 2000). Studies in 
glioblastomas have shown that the activity of telomerase may be an important marker 
of brain tumor malignancy (Nakatani, Yoshimi et al. 1997). Other studies done on 
brain tumor tissues show that telomerase reactivation is an essential event in the 
neuroepithelial cell immortalization in vitro (Hiraga, Ohnishi et al. 1998). Indeed, the 
detection rate of telomerase activity was examined in astrocytic tumors, where the 
detection rate was 20.0% (3 of 15) for grade II astrocytomas, 40.0% (6 of 15) for 
anaplastic astrocytomas, and 72.3% (34 of 47) for glioblastomas (Hiraga, Ohnishi et 
al. 1998). The concept of telomerase reexpression as a cause for genomic instability, 
however, is not uniformly accepted. It is likely that genomic instability is a multi-
factorial process. 
 
 
2.6. High aerobic glycolysis 
 
 
Glucose. During aerobic glycolysis, glucose is taken up by specific transporters, 
GLUTs where it is converted first to glucose-6-phosphate by hexokinase and then to 
pyruvate, oxidized to HCO3 and reduced into lactic acid in the presence of oxygen. 
This process is called the “Warburg effect” (Warburg 1956). A common property of 
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invasive cancers is an altered glucose metabolism and increased aerobic glycolysis. 
This is only observed in cancer cells (Yamamoto, Seino et al. 1990; Smith 1999), 
whereas in most mammalian cells, glycolysis is inhibited in the presence of oxygen, 
which allows mitochondria to oxidize pyruvate to CO2 and H2O (Gatenby and Gillies 
2004). 
Tumors are able to adapt their metabolism to survive under conditions of reduced 
oxygen availability by increasing glycolysis to maintain ATP production. But, if 
oxygen is not sufficiently supplied, under hypoxic conditions, cells become necrotic 
and a set of genes are induced by the hypoxia inducible transcription factors (HIF) 
that allow them to overcome hypoxic conditions by inducing angiogenesis. This is 
specifically the case for grade IV astrocytoma or GBM (Van Meir 1996; Kaur, 
Khwaja et al. 2005). In addition, under hypoxic conditions, some of the cells can 
acquire new mutations that allow them to grow and form new clones. The 
heterogeneity of these tumors parallels their aggressiveness. 
An increased glucose uptake in cancer cells can be visualized through the clinical 
application of the imaging technique positron-emission tomography (PET) which uses 
the glucose analogue tracer fluorodeoxyglucose (FDG) (Novak, Molnar et al. 2005) 
(Annex 4). Imaging of thousands of oncology patients has demonstrated that most 
primary and metastatic human cancers show a significantly increased glucose uptake. 
The acceleration of glucose uptake and trapping occurs because of the upregulation of 
glucose transporters, notably GLUT3 (Boado, Black et al. 1994), but also GLUT1, 
and hexokinase II (Muzi, Freeman et al. 2001). These studies have correlated poor 
prognosis and increased tumor aggressiveness with increased glucose uptake, 
demonstrating the clinical importance of glucose metabolism in glioblastomas 
(Nelson, Wang et al. 1996) (Annex 5).  
The high glycolytic activity of brain tumors leads to a considerable production of 
lactate. Lactate metabolism in normal brain tissue has been characterized by nuclear 
magnetic resonance (NMR) studies after infusion of 13C-labeled lactate (Hassel and 
Brathe 2000). These studies have demonstrated that, depending on its blood 
concentration, lactate is able to cross the blood–brain barrier and penetrate the brain 
tissue, where it behaves as a preferred neuronal substrate. 
Lactate. A particular type of glial cells, the astrocytes, plays a central role in 
regulating brain energy metabolism. Of particular interest was the observation that 
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astrocytes responded to a prominent index of neuronal activity, the excitatory 
neurotransmitter glutamate, by enhancing both glucose use and lactate production 
(Pellerin and Magistretti 1994). A transfer process between astrocytes and neurons 
was proposed, a concept that came to be known as the astrocyte-neuron lactate shuttle 
(Bittar, Charnay et al. 1996). The first component of the shuttle is constituted by the 
metabolic response of astrocytes to glutamate at excitatory synapses. An enhancement 
of aerobic glycolysis, defined as preferential glucose use and lactate production 
despite sufficient oxygen levels to support oxidative phosphorylation, occurs in 
astrocytes in response to neuronal activation at glutamatergic synapses. Lactate is 
released in the extracellular space where it adds to a preexisting extracellular pool. 
The second part of the shuttle concerns lactate use by neurons. It was clearly 
demonstrated recently that lactate is the preferential oxidative substrate for neurons 
but not for astrocytes, as compared with glucose (Bouzier-Sore, Voisin et al. 2003). 
Because the concentration of lactate in the extracellular space was found to be at least 
similar if not superior to glucose concentration under resting conditions (Abi-Saab, 
Maggs et al. 2002), it is likely that a substantial part of neuronal energy needs will be 
covered by lactate.  
The concept that glucose is the major energy substrate provided by the circulation to 
the adult brain seems to hold true, even if under a number of circumstances, other 
substrates can contribute significantly to cover at least part of brain energy needs. 
Lactate and ketone bodies have been also demonstrated to provide a significant 
energy source for the brain during development but also in abnormal situations such 
as diabetes, prolonged starvation, or hypoglycemia (Abi-Saab, Maggs et al. 2002). 
 
 
3. Targeted chemotherapy against GBMs 
 
 
Therapeutic approaches for GBMs are multidisciplinary, involving surgical excision 
followed by radiotherapy and chemotherapy (Stupp, Mason et al. 2005). Despite 
prolonging survival, treatment of high-grade tumors essentially remains a 
compromise between control of tumor growth and maintenance of quality of life. 
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Modern imaging techniques have greatly improved surgical accuracy, but 
complications of surgical intervention are exacerbation of neurological deficit as well 
as the risk of infection, seizures, bleeding and cerebrospinal-fluid leakage. Even wide 
surgical resection inevitably leaves a large population of viable tumor cells (some 
108–109 cells) and is further limited by the need to conserve essential areas. 
Radiotherapy is well established in the treatment of brain tumors, extending life 
expectancy in the case of highly proliferative tumors by a factor of about two. 
Radiation is active against dividing cells which may form a relatively small 
proportion of the tumor mass. Late reactions like radiation-necrosis can occur after 
treatment. Radiotherapy principally affects the microvasculature, leading to the 
occlusion of small vessels and subsequent necrosis. Necrosis caused by radiation most 
commonly affects the white matter. Infants are more susceptible to its effects because 
of their incomplete state of myelination. In this perspective, chemotherapy is the first 
line of treatment following surgery for children and adults that do not respond well to 
radiotherapy. One traditional treatment for brain tumors involves non-specific 
cytotoxic drugs which act through damaging of DNA, like Taxol-like drugs 
(Dietzmann, Kanakis et al. 2003), or cisplatin, (Ashby and Shapiro 2001) since other 
targeted therapies are uneffective. However, these drugs have a marginal impact on 
patient survival (Rich and Bigner 2004). Nitrosoureas are moderately active against 
CNS tumors since they are soluble in lipids, a property that enables crossing the 
blood-brain barrier. Temozolomide permits slightly to prolonge survival in selected 
GBM patients from 12 to 14 months when combined with radiotherapy (Stupp, 
Mason et al. 2005). The actions of such drugs are poorly understood. They can 
damage renal functions, affect bone marrow cells and cause peripheral nerve 
problems, besides being markedly immunosuppressive. Thus, the medical need for 
more effective cancer chemotherapies remains crucial. 
 
 
3.1. Mechanisms of resistance of GBMs to chemotherapy 
 
 
Normal cells, when submitted to external stress, induce cell cycle arrest, DNA repair, 
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or apoptosis whereas GBM cells have lost several safeguard mechanisms and evade 
these controls by mutating specific regulators of cell cycle arrest and apoptosis 
(Maher, Furnari et al. 2001). In addition, uncontrolled invasiveness and critical 
location makes the handling of primary gliomas a great challenge in oncology. 
Whereas efficient chemotherapeutic treatments have been developed for other 
cancers, none of them is currently effective for most GBMs, despite improved 
knowledge about genetic alterations and the understanding of molecular mechanisms 
involved in the development of brain tumors. Several factors may explain the 
resistance of glioma to drugs and the delay in developing efficient therapies against 
brain tumors.  
 
Contributions to the mechanism of drug resistance by the genetic background. 
The role of TP53, RB and mitogenic pathways has been dissected on the molecular 
level by studying genetically engineered mice models in order to define possible 
routes that lead to the development of gliomas. Only one or two elements of the 
growth factors/Ras/Raf/MEK/ERK, PI3K/PTEN/AKT/mTOR, p53/ARF/MDM2, and 
p16/Rb/cyclinD/CDK4 pathways are targeted in these animal models. Holland and 
collegues have shown that the expression of K-RAS and AKT (Holland, Celestino et 
al. 2000), PDGF-B (Dai, Celestino et al. 2001) or EGFR (Holland, Hively et al. 1998) 
can induce gliomas. Van Dyke (Xiao, Wu et al. 2002) has used tissue-specific 
expression of a RB inhibitor to generate brain tumors facilitated by disruption of 
PTEN expression. DePinho (Bachoo, Maher et al. 2002) found that activation of the 
EGFR pathway in a p16INK4A-null background induced astrocytic dedifferentiation 
and glioma formation.  
A number of studies has demonstrated that expression of p21/WAF1/Cip1 causes a 
G1 cell cycle arrest protecting cells against chemotherapeutic agents (Fueyo, Gomez-
Manzano et al. 1998; Burgess, Pavey et al. 2001; Schmidt and Fan 2001). 
p21/WAF1/Cip1 is a p53-inducible negative cell cycle regulator, and appears to 
mediate p53-dependent cell cycle arrest, but not apoptosis, via damaging DNA 
(Gorospe, Cirielli et al. 1997). Studies using cells from p21 knockout mice have also 
shown that p21-deficient cells are more sensitive to the induction of apoptosis by 
chemotherapeutic drugs and more defective in the repair of DNA damage than normal 
cells (Waldman, Lengauer et al. 1996). Interestingly, elevated p21 expression has 
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been shown in most gliomas suggesting a significant therapeutic window to be 
targeted (Arvanitis, Malliri et al. 1991; Jung, Bruner et al. 1995; Tsumanuma, Tanaka 
et al. 1997). Other studies claim the necessity of p21/WAF1/Cip1 for the induction of 
cell death in cancer cells, via HDAC inhibitors, as it is the case in the MCF-7 cell line 
(Chopin, Toillon et al. 2004). Mice lacking p21CIP1/WAF1 undergo normal 
development but are defective in G1 checkpoint control. (Deng, Zhang et al. 1995). 
Studies investigating the anti-tumor potential of p21 have shown that p21-null mice 
do not develop tumors, at least not at an early age (Jackson, Adnane et al. 2002). 
Molecular analysis of the p21 gene has been performed in diverse types of human 
tumors in which studies, 7 out of 102 (7%) human tumor samples were identified 
having point mutations within the coding region of the p21 gene; two of them showed 
gene rearrangements. The results suggest that the frequency of genetic alterations in 
the p21 gene is relatively low compared to several known tumor suppressor genes 
(Watanabe, Fukuchi et al. 1995) and may represent the background rate of mutations 
in genetically unstable cells.  
The finding that different genetic alterations of the p53, RB and mitogenic pathways 
can generate malignant gliomas indicates that combinatorial molecular therapies 
simultaneously targeting crucial cellular pathways might be more successful than 
those disrupting a single pathway. However, all current chemotherapies that are 
targeting only one or two pathways are ineffective against gliomas.  
 
Epigenetic and genetic alterations renders GBMs resistant to chemotherapy. In 
contrast to findings obtained from animal models, many more genes and pathways are 
affected in human gliomas due to a most severe mutator phenotype that causes to the 
accumulation of epigenetic and genetic alterations (Merlo 2003). DNA methylation 
and histone deacetylation have a central role in the control of gene expression 
including transcriptional repression of tumor suppressor genes. These processes 
influence malignant cell transformation (Hanahan and Weinberg 2000). Methylation 
occurs only at position 5 of cytosines to guanosines in the normal mammalian 
genome. CpG dinucleotides have been progressively depleted from the eukaryotic 
genome during evolution (Herman, Merlo et al. 1995; Baylin and Herman 2000; 
Esteller 2002). Small CpG regions, so-called “ CpG islands”, are protected from 
methylation and are located within promoters of 40 to 50% of human genes, allowing 
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active transcription, whereas the remaining CpG have a high frequency of 
methylation. A growing number of tumor suppressor genes harbor dense methylation 
in normally unmethylated promoter CpG islands (Herman, Latif et al. 1994). Such 
changes contribute as much to tumor growth as do actual mutations, since 
methylation of CpG islands is associated with delayed replication of associated genes, 
chromatin condensation and inhibition of transcription initiation. The original 
indication that methylation status might be relevant in brain tumorigenesis came with 
the finding that the tumor suppressor gene p16INK4, encoding the cyclin-dependent 
kinase inhibitor, is methylated in its promoter in 25% of gliomas but not in normal 
brain (Merlo, Herman et al. 1995; Costello, Berger et al. 1996). Another example is 
the loss of DNA mismatch repair due to the methylation of the human mutL 
homologue 1 (hMLH1) gene promoter resulting in resistance of cancer cells to 
cisplatin in vitro and in vivo (Plumb, Steele et al. 2004). DNA methylation is linked to 
regulation control of gene expression. The functional implications of the association 
of methylation with transcriptionally repressive chromatin have been outlined (Hong, 
Bollen et al. 2003). Recent work has demonstrated that methylated CpG dinuclotides 
are recruiting histone deacetylases (HDACs) (Baylin and Herman 2000). HDACs are 
repressing transcription by deacetylating the amino groups on lysine residues in the 
amino-terminal tail domains of the histones. Knudson’s hypothesis that “two hits” 
(Knudson 2001) are required for the full inactivation of a tumor suppressor gene has 
been shown to be fundamentally correct in almost all cases of human cancer (Jones 
and Laird 1999). The “two hits” by which tumor suppressors become disabled, are the 
intragenic mutations and the loss of heterozygosity (LOH) and homozygous deletion . 
The highest frequency of loss of heterozygosity (LOH) in glioblastoma cell lines is on 
chromosome 10q (Maier, Comparone et al. 1997; Maier, Zhang et al. 1998). PTEN on 
10q23.3 was the first tumor suppressor gene identified (Li, Yen et al. 1997). 
Alternative reading frames on the CDKN2A locus on chromosome 9p21 encode two 
different cell cycle suppressors, called p16INK4Aand p14ARF. Homozygous deletions of 
the p16/CDKN2A gene are found in 69% of glioblastoma cell lines (Ishii, Maier et al. 
1999) and in 45% of human GBMs (Labuhn, Jones et al. 2001), and the p14ARF gene 
was always co-deleted with the p16 gene. This high genetic instability developed 
during brain tumorigenesis leads to overgrowth of precursor cell populations with 
increasingly malignant tumor cell clones that develop higher resistance to selective 
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chemotherapy. Studies on the involvement of methylation in carcinogenesis have 
established this epigenetic modification as a third pathway to the loss of function and 
as one potential hit. Such findings show that there are multiple mechanisms that may 
lead to the generation of high–grade gliomas. In this perspective, DNA methylation 
and deacetylation become targets for cancer therapy. Understanding the roles of 
hypermethylation and histone deacetylation in cancer (Lund and van Lohuizen 2004) 
has clear implications on the therapeutic use of agents targeting the DNA methylation 
machinery and HDACs (Johnstone 2002; Noble and Dietrich 2004; Szyf, Pakneshan 
et al. 2004; Suzuki, Nagano et al. 2005). 
 
Blood-brain barrier (BBB): an obstacle to drug delivery. Drug delivery is a major 
obstacle for successful treatment of malignant gliomas because of the BBB (Nagane, 
Huang et al. 1999). The BBB is a dynamic interface between the blood and the brain 
(Annex 6) (de Boer, van der Sandt et al. 2003), located on the endothelial cells of the 
blood capillaries of the brain, it eliminates (toxic) substances from the endothelial 
compartment and supplies the brain with nutrients and other compounds. Thus, it 
restricts pharmacological accessibility, thereby limiting the accumulation of many 
drugs in the brain. This anatomical barrier is provided by tight junctions between 
endothelial cells and involves various transport systems at the BBB including P-
glycoprotein (P-gp), a major ATP-dependent efflux pump consisting of the multidrug-
resistance 1 gene (mdr1). The expression of P-gp was investigated in the brain where 
the protein might transport paclitaxel and other drugs away from central nervous 
system (CNS) tumors. It was found that P-gp is expressed at high levels in intact rat 
and human brain capillaries at the luminal surface of the endothelium, a location that 
could restrict permeation of drugs into the CNS (Fellner, Bauer et al. 2002). When 
human glioblastomas were transplanted into the brains of mice, the blood vessels 
developed within the tumors also expressed high levels of P-gp (Fellner, Bauer et al. 
2002). Although frequently not intact in the center of malignant brain tumors, the 
presence of an intact BBB at the proliferating and especially invasive edge of a tumor 
beyond visible tumor margins has been proposed as a major factor for the failure of 
chemotherapy for brain tumors (Pardridge 2003). As delivery into the CNS can cause 
numerous side effects like leukencephalopathy, most agents are specifically designed 
to have limited intracranial distribution. This is why potentially effective anti-cancer 
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drugs will be of limited use for the treatment of CNS tumors. The design of a targeted 
therapy for glioma treatment should take into account high selectivity for tumor cells 
relative to normal cells, efficient delivery into the brain parenchyma and limited 
toxicity (Lesniak, Langer et al. 2001).  
 
 
3.2. Choice of drugs and combinatorial strategy  
 
 
Genetics of human tumors and genetically engineered mouse models have improved 
the understanding of the molecular biology underlying glioma pathogenesis and have 
revealed abnormalities in a set of common cellular pathways and functions among the 
majority of these tumors that are now being targeted by novel agents in preclinical 
and clinical development (Merlo 2003). Such targeted agents offer the promise of 
improved tumor control with limited toxicity. Still, significant challenges in their 
development remain: the inability to predict tumor response and limitations of drug 
delivery into the tumor. Indeed, the lipid-mediated free diffusion of a drug through 
the BBB requires lipid solubility and a molecular mass less than about 400–500 Da. 
Most of the drugs that are selected as drug candidates by receptor-based high-
throughput screening programs lack these dual characteristics and do not undergo 
transport across the BBB without the intervention of brain drug-targeting technology 
like liposomes or the infusion of agents into surgical resection cavities. For example, 
breast cancer patients treated with trastuzumab (Herceptin; Genentech/ Roche) have a 
significant rate of recurrence with brain metastases probably due to failure of 
antibody delivery into the brain. 
In order to design a targeted for gliomas, high selectivity for tumour cells relative to 
normal cells, facilitated delivery to the brain parenchyma across the BBB and limited 
toxicity have to be taken into consideration. Several protein kinase inhibitors have 
been developed by pharmaceutical companies and are under preclinical and clinical 
evaluation. Measurement of biomarkers has become an essential element of targeted 
therapies by translating the in vivo efficacy of the drug to a tissue or cell culture 
model. The biomarker can be the target itself or an indirect marker. The target has to 
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be expressed in a high percentage of tumor cells but not in the surrounding normal 
tissues. It must be active in the tumors in which it is expressed and contribute to the 
tumor-phenotype. 
One example for targeted therapies are drugs designed to specifically target tyrosine 
or serine/threonine kinase activity. The kinase regions bind ATP molecules and 
transfer phosphate groups to either the receptor or signaling transducers to initiate 
pathway activation. Pharmaceutical companies have screened large chemical libraries 
of ATP mimetics to develop selective inhibitors of kinases of interest. Recent 
enthusiasm has been generated by the remarkable success of some small-molecule 
protein kinase inhibitors (PKIs) in selectively inhibiting tumour growth. Imatinib 
mesylate (Glivec/ Gleevec/STI571/Novartis), which blocks the kinase activity of 
BCR-ABL, ABL, c-KIT and PDGF receptor (PDGFR), has been successful in the 
control of chronic myelogenous leukaemia (CML), and of gastro-intestinal stromal 
tumours (GIST) (Manley, Breitenstein et al. 2004), (Russell, Brady et al. 2003). 
Gefitinib (Iressa; AstraZeneca), an inhibitor of EGFR-TK activity, is the first targeted 
agent to be approved for the treatment of patients with advanced non-small-cell lung 
cancer (NSCLC) (Krishnan, Rao et al. 2003). Due to the small molecular size, PKIs 
might offer benefit in terms of delivery, but their polarity might limit intracranial 
delivery. Further drug design will permit increased lipophilicity or selective 
intracranial penetration.  
Nevertheless, despite the relatively recent development of novel targeted therapies, 
several potential resistance mechanisms to these agents have become apparent. This is 
the case of chronic myelogenous leukaemia expressing BCR-ABL with resistance to 
Glivec (Bakalova, Ohba et al. 2003; von Bubnoff, Peschel et al. 2003; Weisberg and 
Griffin 2003), this resistance is associated with mutation of the ATP-binding site of 
ABL. Cell lines treated with inhibitors of growth-factor-receptor tyrosine kinases 
often regrow with increased expression of other mitogenic growth factors. Preclinical 
studies of GBMs resistant to inhibitors of the kinase activity of EGFR might have 
resistance due to activation of IGFR1/PI3K/AKT pathway (Jones, Goddard et al. 
2004).  
 
Because of the appearance of mechanisms of resistance, broad-spectrum kinase 
inhibitors or combination of inhibitors have been developed. Another possible 
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approach includes the simultaneous targeting of upstream (receptor) and downstream 
(intracellular) targets. Recent studies showed that the growth of GBMs might be 
synergistically inhibited with the combination of a tyrosin kinase C inhibitor (TKI) 
targeting EGFR and a mTOR inhibitor (Goudar, Shi et al. 2005). The complexity of 
these strategies might be increased by the need of a sequential application in order to 
avoid negative interactions. Some agents might require cycling cells for the induction 
of cell-cycle arrest. In addition to the combined use of inhibitors, targeted therapies 
are already under evaluation in combination with unspecific cytotoxic treatments like 
radiation or chemotherapy (taxol-like drugs, cisplatin, HDAC inhibitors an so on). 
Preclinical studies have shown additive and synergistic effects by these approaches. 
The mTOR inhibitor CCI-779 has shown to synergize with tamoxifen in tamoxifen-
resistant breast carcinoma characterized by high AKT activity (deGraffenried, 
Friedrichs et al. 2004; Dutcher 2004) and synergizes with the inhibitor of EGFR’s 
tyrosine-kinase (EGFR-TK) AEE788 (Novartis) in GBMs (Goudar, Shi et al. 2005). 
(Annex 7).  
 
The goal of the thesis was to define, in vitro, an efficient chemotherapeutic treatment 
for human gliomas, since no real progress has been made in the domain of 
neurooncology with regard to drug development. In this work, human glioma cell 
lines were used as experimental tools for pre-clinical studies of various drugs that are 
already in clinical trials for the treatment of other cancers. Each cell line differs in its 
genetic background and is unique and representative of an individual patient. (Annex 
8: glioma cell lines’ table), (Ishii, Maier et al. 1999). We were focusing on four 
classes of drugs. The protein kinase inhibitors (biologicals) are specifically targeting 
tyrosine or serine/threonine kinases. These drugs are downregulating pathways that 
regulate cell growth, survival, invasion or angiogenesis. Among them, AEE788, 
Glivec and RAD001 are inhibiting EGFR/VEGFR, PDGFR and mTOR respectively. 
Cytotoxic drugs, including histone deacetylases (HDACs) inhibitors like trichostatin 
A (TSA), suberoylanilide hydroxamic acid (SAHA), sodium butyrate (SB) and 
LAQ824 and microtubule dynamics blockers, like epothilones (e.g. EPO906A) or 
taxol, are less specific drugs. HDACs inhibitors target the epigenetic modifications in 
the promoter of a set of important genes regulating cell cycle, survival and 
proliferation, whereas taxol-like drugs are blocking mitosis by inhibiting 
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polymerization and depolymerization of microtubules. The use of glycolytic 
inhibitors, like 2-deoxy-D-glucose (2-DG) represents an innovative additional way to 
block signaling pathways, since tumor cells are highly dependent on ATP for 
regulating growth and survival. This choice was suggested by the results obtained by 
FDG-PET studies in humans with solid tumors that showed significantly increased 
glucose uptake, even more drastic in brain tumors (Annex 4). The non-steroidal anti-
inflammatory drug (NSAID) Indomethacin is an inhibitor of the cyclo-oxygenase 
overexpressed in GBMs. The drugs we used in this study are described individually as 
follow: 
 
AEE788.  
 
AEE788 inhibits both the epidermal growth factor (EGF) and the VEGF receptor 
tyrosine kinase family members. AEE788 is a small-molecule ATP mimetic that 
inhibits EGFR/VEGFR-associated kinase activity. EGFR is a transmembrane 
glycoprotein that mediates the response of cells to mitogenic polypeptides belonging 
to the EGF family as the epidermal growth factor (EGF). EGFR plays fundamental 
roles in development, cell proliferation and differentiation, and has been implicated in 
the deregulation of cell proliferation associated with human cancer, like breast cancer 
or GBM (Nathoo, Goldlust et al. 2004). The majority of GBM have aberrant EGFR 
activity through EGFR over-expression, amplification or mutation. The most common 
of these, the EGFRvIII, involves the loss of exons 2-7 that results in a loss of the 
extra-cellular ligand-binding domain and constitutive activation of the receptor. 
EGFR expression has been linked to decreased survival in patients with malignant 
gliomas. Most solid tumors establish their blood supply by forming vessels to allow 
unrestrained growth (Folkman 1996). Inhibition of VEGF-induced angiogenic signals 
will selectively target the tumor-associated vessels since VEGF-mediated endothelial 
cell proliferation in the normal vasculature is a rare event. In addition, EGFR 
inhibitors can inhibit production of VEGF by tumor cells; a more potent anti-tumor 
response may be achieved through the concomitant inhibition of both EGF and VEGF 
receptors. 
Previous results indicate that there is potential for improved responses by combining 
EGFR inhibitors with other drugs. For example, the combination of gefitinib (Iressa, 
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ZD1839) with radiation therapy in non-small-cell lung cancer, head-and-neck 
cancers, and other solid tumors (Ochs 2004) or the synergistic interaction between 
gefitinib and paclitaxel against human gastric carcinoma cells. (Park, Lee et al. 2004). 
However, no efficient combinatorial effects have been reported on GBM so far. 
Currently, there are some ATP-competitive EGFR and VEGFR tyrosine kinase 
inhibitors in different stages of clinical development (Traxler, Allegrini et al. 2004). 
AEE788, as an anticancer agent, targets deregulated tumor cell proliferation as well as 
angiogenic and migratory capacities (Nathoo, Goldlust et al. 2004). AEE788 is 
currently in phase I clinical trials. 
 
Glivec or Gleevec or STI571 or imatinib.  
 
The tyrosine kinase inhibitor, Glivec, is an example of a selective targeted oncologic 
therapy that induces improved survival in patients with chronic myelogenous 
leukemia (CML). Glivec is inhibiting specifically the Bcr-Abl kinase, a fusion protein 
with enhanced tyrosine kinase activity resulting from the Philadelphia chromosome 
(Ph) present in 95% of CML patients and formed by the translocation between 
chromosome 9 and 22, replacing the first exon of c-abl with sequences from the BCR 
gene. Glivec is an ATP-competitive inhibitor blocking the oncoprotein c-Abl and the 
Bcr-Abl fusion protein involved in the regulation of proliferation in CML. PDGFR 
and c-Kit, that play an important role in the proliferation of tumor cells, appeared to 
be two other main targets of Glivec, which block their autophosphorylation (Manley, 
Breitenstein et al. 2004). Gastrointestinal stromal tumors (GIST) are the most 
common mesenchymal neoplasms of gastrointestinal tract. The tumors occur in the 
whole gastrointestinal tract and express the cell surface transmembrane receptor KIT 
that has a tyrosine kinase activity and is a product of the c-kit protooncogene. Since 
PDGFR is involved brain tumors, Glivec appeared to be an interesting drug to be 
tested in human gliomas cell lines, as a single agent or combined with other drugs 
(Capdeville, Buchdunger et al. 2002). 
In previous studies, Glivec has already been combined with other drugs for various 
cancer treatment. The microtubule-stabilizing agent Epothilone B (EPO906) 
combined with Glivec showed a positive interaction by exhibiting an anti-tumour 
effect using rat C6 glioma xenografted in nude mice (O'Reilly, Wartmann et al. 2004). 
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Glivec was tested in combination with radiotherapy (Russell, Brady et al. 2003) and 
in combination with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) to 
overcome the resistance observed against Glivec during the treatment of a CML blast 
crisis (Nimmanapalli, Fuino et al. 2003; Nimmanapalli, Fuino et al. 2003; Yu, 
Rahmani et al. 2003). In another study, the mTOR inhibitor rapamycin enhanced 
Glivec-mediated killing of CML cell lines in vitro by overcoming Glivec resistance in 
cells with Bcr-Abl gene amplification (Ly, Arechiga et al. 2003). 
 
RAD001.  
 
RAD001 is an analog of rapamycin, a natural product derived from the soil bacteria 
Streptomyces hygrosopius, approved for use in organ transplantation in 1999 due to 
its immunosuppressive property. Studies demonstrated antitumor activity, although 
initially the mechanism was unknown. 
Rapamycin targets the serine/threonine protein kinase mTOR (mammalian target of 
rapamycin), a key regulator of cell cycle and growth. The drug does not directly 
inhibit mTOR, but binds to its immunophilin, FK binding protein (FKBP12). This 
complex then interacts with mTOR inhibiting its function and leading to reduced cell 
growth and proliferation. The downstream effects of rapamycin include inhibition of 
translational pathways, with loss of phosphorylation of the eukaryotic translation 
initiation factor 4EBP-1 (4E binding protein-1), and with inhibition of the 40S 
ribosomal protein kinase p70S6, blocking ribosomal biogenesis and mRNA 
translation. This effect results in a 15% to 20% reduction of overall protein levels and 
leads to cell cycle arrest. Other cellular functions that appear to be regulated by 
mTOR include actin organization, membrane trafficking, protein degradation, protein 
kinase C signaling, and tRNA synthesis (Schmelzle and Hall 2000). There are also 
regulatory effects on synthesis of essential cell cycle proteins, such as cyclin D1 and 
c-myc. Other data suggest that mTOR regulates protein synthesis when cellular ATP 
levels fluctuate (Dennis, Jaeschke et al. 2001).  
Important upstream regulators may be altered in tumor cells as it is the case in 
glioblastoma. Both PI3K and Akt are thought to be upstream to mTOR, regulated by 
the tumor suppressor protein PTEN. (Inoki, Corradetti et al. 2005). An additional 
pathway influenced by mTOR involves the hypoxia-inducible factor (HIF). The 
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accumulation of the oxygen-sensitive transcription factors HIF-1 and HIF-2 leads to 
an increased stimulation of the expression of vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), and transforming growth factor 
(TGF-β). This effect is augmented by the activation of mTOR which increases HIF-1 
activity (Brugarolas, Vazquez et al. 2003). In mice, rapamycin may inhibit production 
of the vascular endothelial growth factor VEGF that leads to a remarkable inhibition 
of tumor growth (Guba, von Breitenbuch et al. 2002).  
In addition to its role in regulating cell proliferation, growth, differentiation, and 
survival, mTOR can control whether a cell undergoes programmed cell death type I 
(apoptosis) or type II (autophagy) (Castedo, Ferri et al. 2002). Rapamycin induces 
apoptosis in a cell type–specific fashion, yet in some cells in which rapamycin 
inhibits mTOR it stimulates autophagy rather than apoptosis (Shigemitsu, Tsujishita 
et al. 1999). It is still unclear whether cross-talk occurs between these two 
programmed cell death pathways and what determines why cells die from one type or 
the other. 
It is known that half of glioblastomas have PTEN mutations, which could make them 
increasingly sensitive to mTOR inhibitors, and this is being investigated clinically 
(Sansal and Sellers 2004). Previous reports already showed that rapamycin and its 
derivatives RAD001 and CCI-779, inhibit glioblastoma tumor growth by specifically 
blocking the mTOR protein kinase, (Eshleman, Carlson et al. 2002), (Huang and 
Houghton 2003), (Sawyers 2003). Other studies showed synergism between 
rapamycin derivatives and other drugs, on growth inhibition or apoptosis induction. 
For example, rapamycin has been reported to enhance the efficacy of several 
cytotoxic agents in breast cancers: additive effects were observed in combination with 
doxorubicin and gemcitabine, whereas synergistic interactions were observed in 
combinations with paclitaxel, carboplatin, and vinorelbine (Mondesire, Jian et al. 
2004). In the studies performed in a pediatric brain tumor model (Geoerger, Kerr et 
al. 2001), CCI-779 induced significant growth inhibition and additive effect when 
combined with cisplatin. More recently, the rapamycin derivative RAD001 was found 
to dramatically enhance cisplatin-induced apoptosis in wild-type p53, but not mutant 
p53 tumor cells (Beuvink, Boulay et al. 2005). In In vivo studies, RAD001 was shown 
to improve glioblastoma growth inhibition in combination with AEE788, in a mouse 
glioma xenograft model (Goudar, Shi et al. 2005). RAD001 and CCI-779 are in phase 
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I and II trials, respectively, as anti-cancer agents. But, used as single agents, only 
weak responses have been obtained when used for the treatment of GBM in some 5% 
of patients. 
 
HDACs inhibitors: trichostatin A (TSA), sodium butyrate (NaB) and LAQ824 
 
The accessibility of DNA to proteins such as transcription factors and their co-factors 
is determined in part by a series of chromatin modifying enzymes. The DNA wrapped 
around nucleosomes can be further condensed into higher order chromatin, known as 
heterochromatin and euchromatin. Euchromatin is more transcriptionally active and 
contains most protein encoding genes. The nucleosome itself is made up of an 
octamer of histone proteins, two each of H2A, H2B, H3 and H4, with 145 bp of DNA 
wrapped around it. Modification of the highly charged lysine residues in the N-
terminal histone tail is one mechanism whereby chromatin condensation is controlled. 
These lysine residues are subject to modification by acetylation and methylation, 
which are post-translational modifications that have a considerable impact on 
transcriptional activity (McLaughlin and La Thangue 2004), (Annex 9). 
Histone deacetylases (HDAC) are evolutionarily conserved and expressed in 
organisms from archaebacteria to man and, together with the conversely acting 
histone acetyl transferases (HATs), control the acetylation level of chromatin and 
subsequent transcriptional activity. HDACs remove the acetyl group from histones 
using a charge-relay mechanism consisting of two adjacent histidine residues, two 
aspartate residues and one tyrosine residue. Crucial for this charge-relay system is a 
Zn2+ ion (zinc finger), which binds deep in the pocket of the enzyme. The hydroxamic 
acid-based compound trichostatin A (TSA), fits into the HDAC active site, chelating 
the Zn2+  ion and inhibiting the enzyme at a low IC50 (nM).  
The action of all HDACs inhibitors (HDIs) leads to a restricted alteration of gene 
expression profile since only 2 to 5% of genes, involved in proliferation, 
differentiation and apoptosis regulation, are re-expressed, as it is the case for the gene 
coding for the cyclin-dependent kinase inhibitor p21. This restricted gene re-
expression may explain the apparent low toxicity seen in clinical trials to date. 
Subsequent hydroxamic acid based HDIs, including SAHA, PXD101 and LAQ824, 
are in clinical trials (Monneret 2005). Cancer cells overexpressing the membrane 
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ATPase P-glycoprotein (P-gp), that mediates multidrug resistance, do not exhibit 
resistance to LAQ824, which indicates that LAQ824 is not a substrate for P-gp.  
An important finding in predicting the potential utility of HDIs in the clinics is their 
activity in cell-lines that are resistant to existing chemotherapeutics. For example, 
TSA sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen (Jang, 
Lim et al. 2004). Other interesting results were obtained in CML where Glivec-
resistant Bcr/Abl cells are sensitized to Glivec upon co-treatment with SAHA (Yu, 
Rahmani et al. 2003). 
 
 EPO906: blocker of microtubule dynamics  
 
Drugs that target microtubules are among the most commonly prescribed anticancer 
therapies. EPO906 (epothilone B), is a potent member of a new class of microtubule-
stabilizing cytotoxic agents known as epothilones. Like cytotoxics in the taxane 
family (paclitaxel or taxol), EPO906A exerts its anti-tumor activity effect by 
interfering with microtubule dynamics. EPO906 is able to induce polymerization of 
tubulin dimers into stable microtubules that blocks the cell cycle in G2/M and blocks 
mitosis (Goodin, Kane et al. 2004). Formation of microtubules involves 
polymerization of heterodimeric subunits of α/β-tubulin which involves hydrolysis of 
guanosine 5’-triphosphate and is regulated by several microtubule-associated 
proteins. Intact microtubule function is required for formation and functioning of the 
mitotic spindle, and cells treated with agents that bind either tubulin subunits or 
polymerized microtubules exhibit alterations in spindle formation, as well as arrest in 
the G2/M phase of the cell cycle, which is associated with induction of apoptosis. 
In contrast to paclitaxel, EPO906 is cytotoxic to multidrug-resistant cells 
overexpressing the P-glycoprotein (P-gp) efflux pump and to taxol-resistant cells. 
EPO906 is also able to pass the blood-brain-barrier in animals. Clinical studies have 
shown that DNA damaging agents like cisplatin or microtubule dynamic blockers like 
taxanes are cytotoxic chemotherapeutics, not well tolerated in patients due to their 
narrow therapeutic window of application. With respect to that, a combinatorial 
approach was developed in order to decrease the doses of theses cytotoxic drugs. 
Recent results have already shown interesting combination of epothilones with other 
drugs. For example, O'Reilly et al have observed an enhanced antitumour activity in 
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vivo against experimental rat C6 glioma when EPO906 and Glivec were combined 
(O'Reilly, Wartmann et al. 2004). In another recent study, the glycolytic inhibitor 2-
deoxy-D-glucose increased the efficacy of adriamycin and paclitaxel in human 
osteosarcoma and non-small cell lung cancers in vivo (Maschek, Savaraj et al. 2004). 
 
The glycolytic inhibitor 2-deoxy-D-glucose (2-DG) 
 
The glucose analog 2-deoxy-D-glucose (2-DG) is an inhibitor of glycolysis in all 
eukaryotic cells. 2DG undergoes facilitated diffusion into cells via glucose 
transporters. Once intracellular, 2-DG is phosphorylated by hexokinase which is 
upregulated in cancer cells, yielding 2-deoxy-D-glucose-6-phosphate (2-DG-6-P). 2-
DG-6-P is not a substrate for glucose-6-phosphate dehydrogenase or 
phosphohexoisomerase (Wick, Drury et al. 1957). Therefore, once formed, 2-DG-6-P 
is not further metabolized and will accumulate in the cell until de-phosphorylated by 
phosphatases. The accumulation of the anti metabolite leads to a drop in the cellular 
ATP/ADP ratio and an increase of AMP/ATP ratio. The increase of AMP activates 
the first cellular energy sensor, 5’AMP-activated protein kinase (AMPK) via the 
tumor suppressor LKB1 (Shaw, Bardeesy et al. 2004) and the tuberous sclerosis 
complex TSC1/2 (Inoki, Zhu et al. 2003) that is inhibiting mTOR which then adjusts 
the rate of ribosome biogenesis to the rate of intracellular ATP levels. By activating 
AMPK, mTOR may inhibit protein translation affecting the cell cycle and cell 
proliferation (Horman, Browne et al. 2002). Recently, a role of 2-DG in the 
modification of glycosylation of transcription factors and other essential proteins has 
been reported (Kang, Ju et al. 2003). This modification could alter the activity of 
these proteins, similarly to the phosphorylation status.  
2-DG appears to selectively accumulate in cancer cells by metabolic trapping due to 
high intracellular levels of hexokinase or glucose transporters. This trapping is shown 
by the imaging technique positron emission tomography (PET) using the glucose 
analogue tracer 18fluorodeoxyglucose (FDG) in patients with metastatic human 
cancers, which allows quantification of glucose uptake in the whole body compared 
to glucose uptake in the tumor (Wahl, Cody et al. 1991) (Annex 4). By using this 
method, previous studies have demonstrated that FDG accumulates in most of the 
cerebral gliomas and its accumulation correlates with the degree of malignancy (Di 
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Chiro, Brooks et al. 1984). Thus, tumor cells, and most glioblastoma cells, have a 
higher glucose uptake and use a huge part of their energy from the glycolytic pathway 
in order to maintain their high growth and proliferation rates (Gatenby and Gillies 
2004). As tumor cells are highly dependent of ATP, a less conventional strategy 
would be to inhibit the “glycolytic” or the “energetic” pathway, which so far has 
generated little interest in terms of drug development (Aft, Zhang et al. 2002). Thus, 
the inhibition of the glucose transport and glycolysis appeared to be an interesting 
anti-tumor tool to alter tumor proliferation, migration and cell survival.  
Previous studies have shown the effects of 2-DG on cancer cells. Mostly used as a 
tool to mimic glucose starvation, only a few reports have demonstrated that 2-DG, 
used as a single agent, is able to strongly reduce growth of tumor cells (Cay, Radnell 
et al. 1992). Mohanti et al reported the use of 2-DG in combination with radiotherapy 
for the treatment of human gliomas in poor countries (Mohanti, Rath et al. 1996). 2-
DG might induces DNA repair deficiency after radiation leading to apoptosis 
(Dwarkanath, Zolzer et al. 2001).  
 
The Non-Steroidal Anti-Inflammatory Drug (NSAID) Indomethacin (IND) 
 
Cyclooxygenase (COX) catalyzes the rate-limiting step in arachidonate metabolism, 
resulting in prostaglandin production. COX exists as two isoforms: COX-1 is 
constitutively expressed as a house keeping gene in several cell types of normal 
mammalian tissues, where it is involved in the maintenance of tissue homeostasis. In 
contrast, COX-2 is a highly inducible gene in response to various stimuli, like 
lipopolysaccharides and pro-inflammatory cytokines responsible for prostaglandin 
(PG) production. Cyclooxygenase is expressed in the CNS, where it plays a major 
role in inflammation, fever and pain, and is also involved in the sleep-awake cycle, 
body temperature control, cerebral blood flow and neuroendocrine function.  
Normal astrocytes alone do not express COX-1, and COX-2 expression is minimal 
compared to astrocytoma cell lines. In contrast, COX-1, and especially COX-2, are 
expressed in all grades of astrocytomas, and high-grade tumors express higher levels 
of COX-2 than low-grade tumors, which is associated with resistance to apoptosis and 
induction of angiogenesis (Joki, Heese et al. 2000). In addition, recent studies in 
oncology have identified a role for COX-2 in cell proliferation, in cancer control and 
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apoptosis regulation (Zhou, Wong et al. 2001).  
Cyclooxygenase inhibitors became of high interest for glioma treatment, since 
synergy with other forms of therapy was reported (New 2004). NSAIDs affect 
cyclooxygenase in several ways. The NSAID indomethacin is a temporary-dependent 
reversible inhibitor of cyclooxygenase. Aspirin, one of the oldest NSAIDs, 
irreversibly inactivates COX-1 and COX-2 by acetylating a serine moiety at the active 
site. Ibuprofen is a reversible competitive inhibitor. Salicylate alone does not inhibit 
COX-1 or COX-2 activity in vitro, but it is an effective inhibitor of prostaglandin at 
sites of inflammation. Previous studies showed that aspirin and other NSAIDs inhibit 
carcinogenesis in rats, and that both selective and nonselective NSAIDs are effective 
in inhibiting early stages of tumor development. 
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Previous reports have shown that malignant GBMs are resistant to chemotherapeutic 
agents, due to the presence of the blood-brain barrier that is reducing drug diffusion, 
to a high level of genetic instability of tumor cells giving rise to heterogeneity and to 
mechanisms of resistance associated with tumor growth and the accumulation of 
mutations. Thus, the application of one single drug might not be sufficient to induce a 
therapeutic effect on survival or growth of these tumors. Drugs targeting various 
pathways, essential for tumor cell survival and maintenance, have been tested in this 
work. Among them, AEE788, Glivec and RAD001 inhibiting the protein kinases 
EGFR/VEGFR, PDGFR and mTOR respectively were used. The cyclo-oxygenase 
involved in the prostaglandin pathway has been inhibited by indomethacin. The HDIs 
LAQ824, NaB, TSA and EPO906A target HDACs and microtubules, respectively. 
Inhibition of the glycolytic pathway was performed by 2-DG. All these compounds 
have already been used as single agents in humans. However, we investigated if the 
exposure of human GBM cell lines to single or combined drugs could synergistically 
induce cell death at doses that would also be applicable to patients. 
 
 
1. Effects of AEE788, Glivec, RAD001 (so called biologicals) on 
human glioma cell lines after single and combined treatment 
 
 
First, using 10 human GBM cell lines (Annex 8) three “biologicals” have been tested 
in order to determine individual drug concentrations that are necessary to affect 
proliferation and cell survival. In a second set of experiments it was then analysed if 
the use of combinations of these three drugs, at clinical dose ranges, are capable to 
synergistically induce apoptosis. 
 
AEE788 induces apoptosis only at unspecifically high concentrations in human 
GBM cells. 
The EGFR inhibitor AEE788 was tested on LN229, and its effect on cell survival and 
proliferation was tested. Cells were pre-incubated with AEE788 for 1 hour and then 
stimulated for 10 min with EGF. The Western Blot shows that 1 to 10 µM AEE788 
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efficiently inhibits phosphorylation of EGFR after stimulation. 0.1 µM AEE788 is 
able to partially reduce EGFR phosphorylation and 1 µM AEE788 inhibits fully 
EGFR phosphorylation (Fig. 1A). AEE788 reduces proliferation by inducing an 
accumulation of cells in the G1 phase of the cell cycle, after 36 h treatment with 1 µM 
on the drug (Fig. 1B). Increasing concentrations of AEE788 (0.1, 1, 10 µM) were 
applied to the cells for 4 days then cell survival was measured. Weak induction of 
apoptosis occurred at 1 µM and did not exceed 40% apoptosis in 3 out of 10 cell lines 
tested (Hs683, LN18, U373). At 10 µM the percentage of apoptosis reached 90% in 
LN215 and SF767 cell lines and between 50% and 70% in the other cell lines (Fig. 
1C). However, 10 µM is not usable for clinical trials, since serious side effects are 
expected to occur at such high doses. Therefore, 0.5 µM AEE788 was used in 
following experiments. 
 
Glivec weakly induces apoptosis in human GBM cell lines 
Increasing concentrations of Glivec were applied to the GBM cell lines for 4 days and 
survival was determined. Half of the cell lines were refractory to Glivec since no cell 
death was observed in 5 out of 10 cell lines (Fig. 2). Even unspecifically high 
concentration of 10 µM Glivec was only able to induce apoptosis between 20 to 25% 
in half of the lines (Fig. 2).  
 
RAD001 efficiently inhibits proliferation of GBM cell lines but does not induce 
apoptosis. 
A set of mutated PTEN or wild-type PTEN GBM cell lines were exposed to 
increasing doses of RAD001 from picomolar to micromolar ranges for 36 h. The 50% 
inhibitory concentration (IC50) was determined for each cell line (Fig. 3A). The 
results show that the IC50 values of RAD001 are comprised between 2nM and 200 
nM. The results showed also that the most sensitive cell lines are the PTEN mutated 
cell lines for which 2 to 10 nM RAD001 reduced proliferation to 50% (Fig. 3A), 
whereas 200 nM RAD001 are needed to reduce proliferation to the same extent in the 
PTEN wt cell lines (LN229) (Fig. 3A). LN229, SF767, LN401 and U373 cell lines 
were subjected to 20 nM RAD001 for 72 h and the cell cycle profile was determined 
by FACS after propidium iodide staining. The FACS analysis showed an increase of 
the number of all RAD001 treated cells in the G1 phase of the cell cycle when 
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compared to the untreated cells. In addition, the increase was more drastic for mutant 
PTEN than for the wild-type PTEN cells. RAD001 induced an increase of 5 to 10% of 
cells in G1 for LN229 and SF767, whereas an increase of 20% of cells was observed 
for LN401 and U373 (Fig. 3B) suggesting a higher sensitivity of the PTEN mutant 
cells to RAD001. This cytostatic effect is also demonstrated by the dephosphorylation 
of the cell cycle regulatory protein, the retinoblastoma protein (RB), upon RAD001 
treatment in LN229 (Fig. 3C). The effect of 20 nM RAD001 in LN229 was lasting for 
4 to 5 days as shown by the inhibition of the phosphorylation of the downstream 
biomarker, the small abundant ribosomal protein S6 (Fig. 3C). FACS analysis 
revealed that RAD001 did not induce apoptosis in none of the glioma cell lines tested, 
even after a 6 days exposure to 20, 200 or 2000 nM RAD001. In contrary, RAD001 
even lowered the basal level of apoptosis in all 4 GBM cell lines tested (Fig. 3D).  
These data confirm what was found in previous studies in other cancer cell lines 
concerning the highest sensitivity to RAD001 of the mutant PTEN compared to the 
wt PTEN cells. However, RAD001 is not able to induce apoptosis in GBM cells. 
Nevertheless, RAD001 was tested for the use as a sensitizer in combination with other 
drugs, in order to improve their effects on the inhibition of growth or on the induction 
of apoptosis in the human glioma cell lines. The effective concentration chosen for 
RAD001 was 20 nM for further combined experiments. 
 
Only 3/10 GBM cell lines weakly respond to a double or triple combination of 
“biologicals”. 
Various combinations were tested on 10 genetically well characterized GBM cell 
lines, the drugs were added simultaneously for 4 days and cell survival was 
determined by FACS. Three types of responses were obtained featuring different 
resistance of these cell lines to the drug combinations. The first type of response was 
found in 7 out of 10 cell lines. They did not respond to any of the drug combinations. 
The percentages of cell death observed in cells exposed to various drug combinations 
are similar to those observed in the untreated cells, except in presence of RAD001, 
where cell death appeared to be slightly reduced (Fig. 4A). The cell line LN18 
represented the second type of response, with no response to the single agents but 
weak induction of cell death when AEE788 was combined with Glivec. Here again, 
the presence of RAD001 decreased the basal levels of apoptosis, even in the triple 
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combination (Fig. 4B). In the last type of response, LN215 was sensitive to the double 
and triple combinations. In the case of the triple combination, RAD001 increased 
apoptosis (Fig. 4C1). SF767 cell line was sensitive to AEE788, apoptosis was 
increased when AEE788 was combined to Glivec, and reduced in the presence of 
RAD001 in the triple combination (Fig. 4C2).  
Colony formation assays were performed on two cell lines to test the effects of single 
and combined drugs on glioma cell proliferation and colony formation. The results 
showed a drastic reduction of proliferation and colony formation in the SF767 cell 
line, upon AEE788, RAD001 and upon the combined drugs. In contrary, the Hs683 
cell line exhibited more resistance to the AEE788 and/or Glivec, but RAD001 could 
reduce its proliferation by half (Fig. 5). 
 
Conclusions: Glioma cell lines exhibited a very high degree of resistance to the 
single agents AEE788, Glivec and RAD001, but also to double and triple 
combinations with respect to induction of cell death. Only 3 out of 10 cell lines were 
sensitive to some drug combinations, confirmed by a significant induction of 
apoptosis in LN18, SF767 and LN215 cells. However, the resistance or sensitivity of 
the cell lines to the drugs could not be correlated with the known genetic background. 
The results were not predictable and did not depend upon the p53 status (Fig. 6). 
Since these preliminary results obtained by the use of  “biologicals” were 
disappointing, we expected to obtain more encouraging results when “cytotoxic” 
drugs like HDACs inhibitors (HDIs) or EPO906A were used as single drugs or in 
combinations. 
 
 
2. Effects of the “cytotoxics” HDACs inhibitors (HDIs) and 
EPO906A on GBM cell survival  
 
 
Cytotoxic drugs are not targeting specific kinases and act in a much more unspecific 
way. Transcription and the doubling of cells (mitosis) are the respective targets of 
HDIs and EPO906A. By inducing transcription of genes that have been epigenetically 
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silenced during tumorigenesis, the regulation of proliferation is restored and affects 
the behavior of the cancer cell that is finally directed to apoptosis. EPO906 is 
affecting the separation of chromosomes during mitosis that is controlled by 
microtubules. This generates abnormal mitosis that is directing the cells to apoptosis. 
By testing these drugs on our GBM cell lines, we intended to determine their potential 
anticancer effect. 
 
The HDIs LAQ824 selectively induces apoptosis in cancer cells 
Seven glioma cell lines (LN229, LN401, SF767, U343, U373, LN71, Hs683) and the 
normal human embryonic kidney cell line HEK293 were exposed to increasing doses 
of the HDAC inhibitor LAQ824 (0, 10, 60, 200, 500 nM) for 72 h and cell death was 
measured by FACS analysis (Fig. 7A). LAQ824 induced apoptosis in all glioma cell 
lines at nanomolar drug concentrations and the induction of apoptosis (cytotoxicity) 
was dose-dependent. No cell death occurred in the normal HEK293 not even at high 
doses. The results supported the known property that HDIs like LAQ824 selectively 
targets cancer cells. In addition, several other human cancer cell lines originating 
from breast (MCF-7, HBL, SKBR-3), cervix (HeLa) and colon (Calu6), and the 
previous glioma cell lines were subjected to 60 nM LAQ824 for 72 h, in order to 
compare their sensitivity to the drug. In addition, the non-cancer cell line, HEK293, 
the human skin fibroblast cell line (HSF) and the rat aortic smooth muscle cell line 
(RASMC) were treated in the same way. The glioma cell lines were more resistant to 
LAQ824 than the other cancer cell lines, pointing to the obvious resistance of GBM 
towards treatment by such drugs in contrast to e.g. breast or colon tumors (Fig. 7B). 
Induction of cell death occured neither in HEK293 nor in HSF nor in RASMC, even 
at higher LAQ824 doses or after a longer time of exposure (Fig. 7B). 
 
HDIs reduce proliferation in cancer and non-cancer cells 
Cell proliferation was tested in all glioma cell lines at 30 nM HDI LAQ824, a 
concentration where no apoptosis was observed after 72 h exposure. HEK293 was 
also subjected to this treatment in order to know whether the drug affects at least its 
proliferation. Glioma cell lines and HEK293 were exposed for 48 h prior to BrdU 
staining followed by FACS analysis (Fig 7C). The results indicated that all cell lines, 
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GBM as well as normal HEK293, were responding to 30 nM LAQ824 by a 
significant reduction of cell proliferation (Fig 7C). 
 
EPO906 is more cytotoxic for cancer cells than for normal cells 
In the same way, LN229, LN401, SF767, U343, U373, LN71, Hs683 GBM cell lines 
and HEK293 cells were exposed to increasing doses of EPO906A (0, 0.04, 0.2, 1, 5, 
25 nM) for 72 h and cell death was measured (Fig. 7D). The data show that EPO906A 
induced apoptosis in some GBM cell lines in the sub-nanomolar range (1 nM) and 
that the cytotoxicity increased dramatically with higher doses. We only observed 
weak induction of cell death at high doses (25 nM) in HEK293 cell lines. These 
results show, similar to LAQ824, that EPO906A is selectively targeting cancer cells. 
The relative resistance of cancer cells to this drug was reported to be due to potential 
mutations in the β-tubulin, which would confer more resistance to EPO906A 
(Kowalski, Giannakakou et al. 1997) (Fig. 7D)  
 
Conclusions: The results showed that the cytotoxic drugs are inducing apoptosis in 
the GBM cell lines at nanomolar concentrations, whereas they do not induce any cell 
death in non-cancer cells even at high doses. Nevertheless, efficient apoptosis is only 
triggered by high doses of HDIs (500 nM for LAQ824) in GBM cell lines, whereas 
other cancer cells exhibit already strong apoptosis at lower doses (60 nM for 
LAQ824). However, according to other studies performed in humans (Goodin, Kane 
et al. 2004), the disadvantage of using EPO906 in vivo is its significant toxicity. 
Therefore, HDIs were chosen for the combinatorial tests described in the following 
sections.  
 
 
3.  Indomethacin enhances HDACs inhibitors-induced apoptosis 
 
 
The purpose for combining indomethacin with HDACs inhibitors (HDIs) was to 
sensitize cells by indomethacin in order to use lower doses of HDIs. Cyclooxygenase 
inhibitors become of high interest for glioma treatment, since GBMs express high 
levels of cyclo-oxygenase 2 (COX-2). Synergy between NSAIDs and other forms of 
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therapy was already reported (New 2004). In the following experiments, the effects of 
a combined treatment of glioma cell lines with the HDAC inhibitor LAQ824 and IND 
was investigated. 
 
HDI and indomethacin synergistically induced apoptosis in human GBMs. 
Six glioma cell lines were exposed to both increasing doses of the HDI LAQ824 and 
50 µM indomethacin (IND) for 72h, and cell death was determined by FACS (Fig. 
8A). The results revealed that IND, when used as single agent, did not induce 
apoptosis in any of the GBM cell lines tested within 72h. LAQ824 induced cell death 
only at higher concentration (180 nM). However, when both drugs were combined, 
apoptosis was synergistically induced at low LAQ824 doses (10, 30, 60 nM), but the 
induction of cell death was less strong in some cell lines. The synergism is p53-
independent since all cell lines tested exhibited similar effects independently of their 
p53 status.  
 
Indomethacin combined with HDI reduced p21 levels in Hs683 and induced 
apoptosis in other cancer cell lines like MCF-7 and Calu-6. 
In order to determine the mechanism of the synergism, phosphorylation levels of the 
proteins AKT, ERK and S6 and the levels of p21 were analysed 8 h after the exposure 
to 60 nM LAQ824, 50 µM IND or the combination. Interestingly, western blot 
analysis revealed that the increase of p21 caused by LAQ824 was inhibited in the 
presence of IND, whereas the phosphorylation levels of the other proteins were not 
affected (Fig. 9A).  
Other cancer cell lines were submitted to the same drug combination in order to test 
whether the synergism is also induced in non-glioma cell lines. The results indicate 
that a similar synergistic effect on the loss of survival is caused by the combination of 
both drugs. (Fig. 9B). 
 
Indomethacin combined with HDI does not induce apoptosis in the non-cancer 
cell lines HEK293, HSF or RASMC. 
The human embryonic kidney cell line HEK293, the human skin fibroblast cell line 
HSF and the rat aortic smooth muscle cell line RASMC are non-cancer cell lines. 
They were used as controls to test the cytotoxicity of the combination. Increasing 
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amounts of LAQ824 (10, 30, 60, 90, 180 nM) were combined with 50 µM IND for 72 
h. No cell death was observed even when IND was combined with high 
concentrations of LAQ824 (180 nM) which, in contrary, induces strong apoptosis in 
glioma cell lines (Fig 10A,B,C). 
 
Conclusion: According to the results, only tumor cell lines are responding to the 
combined inhibition of HDACs and COX-2 by a strong induction of apoptosis. In 
addition, the results concerning protein analysis in HS683 suggest that p21 could be 
involved in the synergistic induction of apoptosis by HDI and indomethacin.  
 
 
4. Effects of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) on 
human cancer cell lines 
 
 
Since cancer cells have a high rate of glycolysis, we were interested in testing the 
glycolytic inhibitor 2-DG on our glioma cell lines, in order to determine whether 
these cancer cells are sensitive to energy depletion. The goal of the next experiments 
was to find out whether this compound could be used as a potential “sensitizer” to 
enhance induction of cell death when used in combination with other drugs.  
 
2-DG reduces strongly proliferation of glioma cell lines in a dose-dependent 
manner. 
To study the effect of the inhibition of glycolysis on the proliferation of tumor cells, 4 
glioma cell lines, two PTEN wild-type (LN229, SF767) and two PTEN mutants cell 
lines (LN401, U373) were treated with increasing doses of 2-DG (1, 5, 25, 100 mM) 
for 48h in normal medium supplemented with 25 mM glucose. The proliferation rate 
was determined by BrdU incorporation for 1h before the end of the experiment. The 
data obtained showed already a notable reduction of cell proliferation at 1 mM 2-DG 
in the cell lines tested (Fig. 11A). When equimolar concentrations of glucose and 2-
DG were present in the medium (25 mM), cell proliferation was dramatically reduced 
and no proliferation could be measured anymore upon 100 mM 2-DG (Fig. 11A). 
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Thus, 2-DG exhibits a strong cytostatic effect on glioma cell lines, in a dose-
dependent manner.  
 
2-DG induces apoptosis in cancer cell lines, but not in non-cancer cell lines. 
In order to test the sensitivity of cancer cell lines and non-cancer cell lines towards 
the inhibition of glycolysis, glioma cell lines (LN229, SF767, Hs683, U737, LN401, 
U343), other cancer cell lines (HeLa, MCF-7 and Calu-6) and non cancer cell lines 
(HEK293, HSF, RASMC) were exposed to increasing concentrations of 2-DG (1, 5, 
25, 100 mM) for 72 h in medium supplemented with 25 mM glucose and cell death 
was measured by FACS analysis (Fig. 11B). Increased cell death was observed in a 2-
DG dose-dependent manner in all cancer cell lines tested. Nevertheless, 100 mM 2-
DG was inducing much stronger apoptosis in comparison to 25 or 5 mM, whereas 1 
mM 2-DG was not able to induce cell death in any of the cancer cell lines tested. 
PTEN wt cell lines appeared to be more sensitive to 2-DG than PTEN mutant cell 
lines at 100 mM. Other cancer cell lines like HeLa, Calu-6 or MCF-7 appeared to be 
at least as sensitive to 2-DG as glioma cell lines (Fig. 11B). On the other hand, only 
high doses of 2-DG (25 and 100 mM) could induce weak apoptosis in the non-cancer 
cell lines HEK293, HSF or RASMC (Fig. 11B). HSF did not undergo any cell death 
following a drastic glycolytic block (100 mM). These results indicate that the 
inhibition of the use of glucose in the glycolytic pathway is affecting cancer cells by 
efficiently inducing cell death. 
 
Glucose withdrawal induces strong cell death in all cancer cell lines 
Since 2-DG induced cell death in glioma cell lines, the previous cell lines and HeLa 
were incubated in glucose free medium in order to compare the sensitivity of cells to 
the absence of glucose with 2-DG treatment. Cell death was measured by FACS at the 
indicated time points (Fig 11C). The induction of cell death was more rapid and more 
effective following glucose starvation than after exposure to 2-DG, which was the 
case for all cell lines tested except for the SF767 cell line. This cell line appeared to 
be more sensitive towards 25 or 100 mM 2-DG than to glucose starvation. In addition, 
under glucose starvation, the most sensitive cell lines were the PTEN mutants, in 
contrast to their treatment with 2-DG. Cytochrome c release was used as a read-out 
for the induction of apoptosis via the mitochondrial pathway and its release was 
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measured after glucose starvation for 24 h. Cytochrome c release, especially in PTEN 
mutant cell lines, after 24 h incubation in glucose free medium, verifies the induction 
of apoptosis by the mitochondrial pathway (Fig 11C).  
 
2-DG induces the dephosphorylation of the small ribosomal protein S6, but does 
not reduce the phosphorylation of AKT. 
In order to study the involvement of the glycolytic and the PI3K/AKT pathways in the 
2-DG-induced cell death, their respective biomarkers S6 and AKT were studied. The 
total level and phosphorylation level of these two proteins were followed over 16 
hours exposure to 100 mM 2-DG. The results showed that the total levels of the two 
proteins were maintained for at least 16h. As expected, the basal phosphorylation 
levels of AKT (Ser 473) in PTEN mutants were high in contrast to the PTEN wt cell 
lines (Fig 12A). Once treated with 100 mM 2-DG, all the cell lines exhibited a short 
increase in the phosphorylation of AKT that was more visible in the PTEN mutant 
cells, whereas S6 was rapidly and efficiently dephosphorylated in all the cell lines. No 
strong decrease in the levels of p-AKT was observed in the PTEN mutant cells during 
16 h exposure to 100 mM 2-DG (Fig 12A).  
 
2-DG reduces Rad51 levels and induces PARP cleavage. 
Rad51, a protein involved in DNA repair process, is cleaved by caspase-3 and 
subjected to degradation via the proteasome. PARP is also cleaved by caspase-3 and 
is a marker of apoptosis. In order to determine the effect of 2-DG on these two 
proteins, the four cell lines previously used were treated with 100 mM 2-DG for 48 h. 
The proteins were analysed at the indicated times by western blot. The results 
revealed that total protein levels of Rad51 were reduced after treatment for 24h and 
that PARP cleavage is appearing after 36 h of incubation with 2-DG, corresponding to 
the time where apoptosis is induced (Fig. 12B). 
 
Effects of 2-DG on ATP levels and on the activation of AMPK 
ATP levels were examined upon 2-DG exposure or glucose withdrawal conditions, in 
order to determine whether the drop of ATP is initiating the induction of apoptosis 
and whether this drop is similar under the two conditions. U373 cell line was treated 
with increasing concentrations of 2-DG (1, 5, 25, 100 mM) or starved with glucose 
 49
free medium for 48h. The ATP levels were measured at 1, 8, 24 and 48 h after the 
beginning of the treatment. The results show that ATP levels are reduced upon 2-DG 
treatment as well as upon exposure to glucose-free medium. However, ATP levels are 
more dramatically decreased at the beginning of the exposure to 25 mM and 
especially to 100 mM 2-DG than after glucose starvation. Still, even 1 mM 2-DG is 
able to reduce glycolysis consequently lowering ATP levels in presence of 25 mM 
glucose into the medium (Fig. 13A). The results suggest that 2-DG is blocking 
glycolysis and reducing ATP levels by an active process, whereas the drop of ATP, as 
a consequence of glucose withdrawal, might happen via an inactive process following 
the decrease of intracellular stocks of ATP (Fig. 13A) 
In addition, the data show that both, 2-DG and glucose-free medium, reduce ATP 
levels in a two-phase manner with time. A first fast drop occurs between 0 and 1 h 
after the start of the treatment followed by a small increase and a second drop of the 
ATP level after about 24 h. The same two-phase pattern can be observed with the 
activation/phosphorylation of AMPK that is regulated by the AMP/ATP ratio in the 
cell (Fig. 13B). Lower 2-DG did not induce apoptosis since the drop of ATP is less 
drastic and the stock of ATP was sufficient for cell survival.  
 
Pyruvate is not able to rescue cell death induced after exposure to 25 mM 2-DG 
or glucose withdrawal treatment. 
Two moles of pyruvate result from of one mole of glucose during glycolysis. 
Pyruvate then enters the Krebs cycle and the respiratory chain that produces about 
70% of the ATP in the cell. In order to investigate the involvment of ATP levels in 
the survival of cells in absence of glucose (glucose withdrawal) or in the situation of a 
restriction in glucose usage (2-DG), sodium pyruvate was added to the medium in 
presence of 2-DG or in the absence of glucose and cell death was measured after 72h. 
The results indicated that the supplementation of 4.5 g/L pyruvate to 2-DG-treated 
cells or glucose withdrawal only marginally affected the loss of cell survival (Fig. 
13C), since no drastic reduction of cell death was observed in the presence of 
pyruvate. 
 
Conclusions: At 25 mM, 2-DG induces cell death in all tested glioma cell lines. 
PTEN mutant cell lines exhibited a lower sensitivity to 2-DG than PTEN wt cell lines. 
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Compared to other cancer cell lines, glioma cell lines appeared to be less sensitive to 
2-DG. Of note, cell death induced by the treatment of 2-DG is different from that 
induced by glucose withdrawal. Glucose withdrawal induced earlier and stronger 
apoptosis in glioma cell lines in contrast to 2-DG, except in the SF767 cell line. The 
addition of pyruvate did not bypass the induction of apoptosis in the absence of 
glucose or under the block of glucose usage or 2-DG treatment, except for SF767, 
where no cell death is measured after 72 h upon glucose-free medium treatment, in 
the presence of pyruvate. Taken together, it can be concluded that different 
mechanisms are involved in the induction of cell death by 2-DG or glucose 
withdrawal. 
 
 
5. RAD001 delays 2-deoxy-D-glucose-induced apoptosis in human 
glioma cell lines 
  
 
The PI3K/PTEN/AKT signaling pathway is one of the major pathway driving growth 
factor mediated cell survival and glycolysis. The bad prognosis of GBMs is linked to 
mutations or deletions in the tumor suppressor gene PTEN which negatively regulates 
the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) survival pathway. As it is the case 
with many malignant tumors, GBM are characterized by a high proliferation index, 
due to the upregulation of this PI3K/Akt pathway, correlated with an increased 
glucose metabolism through the glycolytic pathway. A common player in these two 
pathways is mTOR. Being downstream of the PI3K/Akt pathway, this protein kinase 
plays a critical role in translation and cell cycle regulation functioning as an energy 
sensor in the cell, since levels of cellular ATP are regulating the phosphorylation 
status of mTOR. The previous results show that the glycolytic inhibitor 2-DG is able 
to induce apoptosis in glioma cells but only at high doses which would not be 
applicable to patients. In addition, 2-DG is reducing phosphorylation of the small 
ribosomal protein S6, through the activation of AMPK (Fig. 11, 12, 13). As before, 
RAD001 blocks efficiently mTOR and reduces glioma cell growth by increasing the 
G1 cell population (Fig. 3). These results suggested that RAD001 could be a 
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“sensitizer” for the induction of cell death in glioma cells that are treated at the same 
time with low 2-DG concentrations.  
 
The combination of 2-DG and RAD001 does not reduce more efficiently the 
proliferation of glioma cell lines than the single drugs do. 
Four glioma cell lines were subjected either to 20 nM RAD001 or to 5 mM 2-DG or 
simultaneously to both drugs for 48 h and cell growth was determined by BrdU 
incorporation for 1 h. FACS analysis showed that 5 mM 2-DG more efficiently 
reduced proliferation of glioma cell lines than did 20 nM of RAD001 in PTEN wt cell 
lines (Fig. 14A). In contrast, RAD001 did not reduce cell growth in PTEN wt cell 
lines, but it strongly reduced proliferation of PTEN mutant cell lines. A slight 
additional inhibition of the proliferation of glioma cell lines was observed in PTEN 
mutant cell lines, when cells were exposed to the combination of 5 mM 2-DG and 20 
nM RAD001 (Fig. 14A).   
 
2-DG more efficiently blocks colony formation of glioma cells than does RAD001 
A colony forming assay was performed of LN229 in order to test the capacities of the 
cells to form colonies upon 2-DG or RAD001 treatment. The data show that 20 nM 
RAD001 alone could reduce colony formation by 25% compared to the control, 
whereas 1 mM 2-DG reduced colony formation by 75%. When 20 nM RAD001 was 
combined with 1 mM 2-DG, the reduction was as strong as 90% (Fig. 14B). It can be 
concluded that the combination of RAD001 and 2-DG inhibits the formation of 
colonies in an additive way. 
 
2-DG blocks whereas RAD001 only reduces migration of glioma cells it. 
2-DG and RAD001 were tested for their ability to block migration. The migration 
capacity of LN229 glioma cell line was evaluated using the wound-healing assay. 
RAD001 was applied 24 h prior to the start of the migration test. The pictures show 
that the untreated cells migrated well to the middle of the wound (Fig. 14C). 2-DG-
treated cells did not migrate, even at 5 mM 2-DG. In contrast, RAD001, even at 2000 
nM, only weakly inhibited migration of LN229 (Fig. 14C).  
 
 
 52
RAD001 reduces 2-DG-induced apoptosis in glioma cell lines. 
It was investigated whether RAD001 was able to increase 2-DG-induced apoptosis in 
glioma cell lines. LN229, SF767, U373 and LN401 glioma cell lines were exposed to 
a combination of 20 nM RAD001 and 25 mM 2-DG for 72 h. No additive induction 
of apoptosis was observed in none of the glioma cell lines tested. RAD001 rather 
decreased apoptosis induced by 25 mM 2-DG (Fig. 15A) as demonstrated by 
Annexin-V staining and PARP cleavage (Fig. 15B,C) in LN401. To investigate 
further this antagonistic effect exhibited by RAD001, it was combined with lower and 
higher concentrations of 2-DG. RAD001 showed a strong pro-survival effect 
independently of the 2-DG concentrations, under the conditions where glycolysis or 
glucose usage is blocked (Fig. 15D). 
 
2-DG is dominant over RAD001 concerning the inhibition of cell proliferation.  
In order to test the effect of the drug combination on cell proliferation and on the cell 
cycle profile, LN401 was exposed for 72 h to increasing doses of 2-DG (0.01, 0,1, 1, 
5, 25, 50, 100 mM) in presence or absence of 20nM RAD001. The total number of 
cells was measured after 72 h. The histogram shows that RAD001 exerts a strong 
anti-proliferative effect in the absence of 2-DG or at concentrations where 2-DG has 
no effect on the proliferation of cells (0.01, 0.1 mM) (Fig. 16A). Indeed, up to 50% 
less cells were observed at these 2-DG concentrations in presence of RAD001 (Fig. 
16A). At concentrations where 2-DG itself is reducing proliferation (1 mM-100 mM), 
the cytostatic effect of RAD001 is hidden by this one of 2-DG. The inhibition of 
proliferation is dominated by 2-DG. 
 
2-DG and RAD001 induce opposite cell cycle arrest in LN401. 
In order to further analyse the effect of both drugs on the cell cycle profile, the cell 
line LN401 was exposed to 2-DG, RAD001 or both drugs for 36 h. The FACS 
analysis showed that RAD001 induced a strong accumulation of cells in G1, whereas 
2-DG induced an accumulation of cells in G2-M of the cell cycle (Fig. 16B). When a 
combination of both drugs were applied, the cell cycle profile became similar to the 
one of the untreated cells (Fig. 16B), suggesting that both drugs were equally 
participating in the regulation of the cell cycle. The levels of cyclin A protein were 
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followed over 72 h after exposure to 2-DG or RAD001. The protein data showed that 
2-DG decreased more efficiently cyclin A than RAD001 did (Fig. 16C). 
 
Effects of 2-DG and RAD001 on phosphorylation of AKT, ERK and S6. 
In order to investigate the pro-survival mechanism of RAD001 in combination with 2-
DG, the cell lines LN229 and U373 were exposed for 8 h to 25 mM 2-DG, 20 nM 
RAD001 or to both drugs. Phosphorylation levels of AKT, ERK and S6 were 
determined using western analysis. The results revealed that the phosphorylation of 
S6 was abrogated by treatment with 2-DG and RAD001 in the PTEN wt LN229 cell 
line (Fig 17A), whereas it was only abrogated by RAD001 in the PTEN mutated 
U373 (Fig 17B). The phosphorylation levels of AKT in LN229 increased after 
treatment with RAD001 or 2-DG and even more with the combination of 2-DG and 
RAD001 (Fig 17A), whereas no striking change was observed in U373 after the 
exposure to the drugs. However, 2-DG decreased phosphorylation of ERK in both cell 
lines (Fig 17A,B). RAD001 alone had no effect, whereas when it was combined with 
2-DG, the phosphorylation levels of ERK were the same as basal levels in LN229 
(Fig 17A). In contrast, no effect was observed in U373 after 8 h exposure to the drugs 
(Fig 17B). Thus, the effects of RAD001 and 2-DG on the activity of these kinases are 
not clear, further experiments need to be performed. 
 
RAD001 delays apoptosis induced by glucose withdrawal in glioma cell lines. 
The question arose whether RAD001 is also able to reduce apoptosis induced by 
glucose withdrawal, as it was the case for 2-DG. In order to analyse that, 20 nM 
RAD001 was added to the cell culture of glioma cell lines using glucose-free 
medium. This treatment was applied to glioma cell lines during the indicated times. 
The data indicated that RAD001 was able to delay apoptosis induced by glucose 
withdrawal (Fig 18A), pointing again to the pro-survival effect exhibited by  RAD001 
in the absence of glucose.   
 
The combination of LY294002 and 2-DG synergistically induces apoptosis in 
LN401 glioma cell line. 
In order to determine the effect on cell survival caused by the simultaneous inhibition 
of the energy pathway and the PI3K/AKT/mTOR pathway on cell survival, the 
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inhibitor of PI3K, LY294002 (LY), was used in order to downregulate efficiently the 
PI3K/AKT/mTOR pathway. The effect of LY is determined by the block of the 
phosphorylation of AKT being under the control of PI3K. First, the phosphorylation 
of AKT was followed over 48 h in order to determine the efficiency of LY. Western 
analysis showed that LY blocked rapidly the phosphorylation of AKT, but the effect 
of the inhibitor is only lasting for 16 h (Fig. 19A). LY was used in combination with 
both drugs to determine whether this drug is able to potentiate the sensitivity of the 
cells towards RAD001 and 2-DG. The combination of 2-DG and RAD001 was 
applied to LN401 for 72 h in presence or in absence of LY and cell death was 
measured by FACS. LY was added every 16 h according to the inhibitory test (Fig 
19A). The results show that the combination of 2-DG and LY have an additive effect 
on the induction of cell death (Fig 19B), whereas the addition of RAD001 in a triple 
combination, strongly reduced apoptosis induced by the combination of the two drugs 
(Fig 19B). Here again, RAD001 exhibited a pro-survival effect. 
 
Conclusions: The results show that the combined treatment of RAD001 with 2-DG 
reduces apoptosis induced by 2-DG in human glioma cell lines acting like an 
antagonistic pro-survival agent. In contrast, the inhibition of the activation of AKT, 
consequently to the inhibition of PI3K by LY triggers additive cell death when 
combined with 2-DG. 
 
 
6. 2-deoxy-D-glucose combined with HDAC inhibitors causes a 
synergistic induction of apoptosis in human glioma cell lines by 
inhibiting p21 upregulation  
 
 
Burgess et al and Rahmani and colleagues showed that the simultaneous exposure of 
cells to agents that increase p21 expression (as HDIs) and agents that downregulate 
p21 levels (like caffeine or LY294002), induce apoptosis (Burgess, Ruefli et al. 
2004), (Rahmani, Yu et al. 2003). 
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Another report (Kang, Ju et al. 2003) indicated that 2-DG dramatically decreases p21 
protein levels. According to these facts, the combination of 2-DG and HDIs like TSA, 
NaB and LAQ824 was investigated using human glioma cell lines to determined 
whether 2-DG is able to sensitize these cells to HDI-induced apoptosis. 
 
2-DG enhances trichostatin A- and sodium butyrate-induced apoptosis in HS683 
and HeLa cancer cell lines. 
HDIs are potent inducers of cell death in immortalized cells and tumor cell lines. To 
investigate the effect of HDIs on loss of survival, we tested first to which extent 
trichostatin A (TSA) and sodium butyrate (SB) are capable to induce apoptosis in the 
GBM HS683 and the cervix carcinoma cell line HeLa and whether 2-DG is able to 
increase HDIs-induced cell death in a combined treatment. Increasing doses of TSA 
and NaB were applied together with 2-DG for 48 or 72h. Strong induction of cell 
death occured in presence of 2-DG and TSA or NaB, whereas both HDIs alone did 
not induce apoptosis when used at low doses (Fig. 20A, B). Since p21 is re-expressed 
after HDIs treatment, p21 protein levels were analysed in both cell lines after 8h 
exposure to TSA or NaB. The results showed an increase of the p21 protein levels 
which was abrogated by co-treatment with 2-DG. Similar observations were made in 
previous studies where HDIs were combined with caffeine (Burgess, Ruefli et al. 
2004), LY (Rahmani, Yu et al. 2003) or with 2-DG (Kang, Ju et al. 2003) (Fig 20C). 
 
2-DG enhances HDIs-induced apoptosis in human glioma cell lines 
Also the new hydroxamic acid based HDAC inhibitor, LAQ824, was investigated on 
glioma cell lines. Increasing amounts of LAQ824 and/or 25 mM 2-DG were applied 
to six glioma cell lines for 72 h. Consistent with results obtained previously with TSA 
and NaB, LAQ824 induced apoptosis in a concentration-dependent manner in all 
glioma cell lines tested (Fig. 21). 2-DG alone had no strong effects on loss of 
survival, whereas the presence of 2-DG drastically enhanced cell death induced by 
LAQ824 in all cell lines tested. This synergism was found to be dependent on the 
concentration of LAQ824 since the effect was moderate at a LAQ824 concentration 
as low as 30 nM, whereas at higher concentrations the combination of 2-DG with 
LAQ824 exhibited the strongest synergism in that 6 times more cell death could be 
noticed at 60 nM LAQ824 in presence of 2-DG compared to use of the single drugs. 
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In addition, the synergism was induced in a p53-independent way since SF767 and 
U343MG glioma cell lines are mutated for the p53 gene and showed similar 
responses following a combined treatment. However, when the concentration of 
LAQ824 was increased up to 180 nM, the enhancing effect of 2-DG was lost because 
apoptosis was extensively induced by LAQ824 itself (Fig. 21). 
 
The synergism induced by the combination of both drugs is concentration-
dependent. 
To test the contribution of 2-DG in this synergism, lower concentrations of 2-DG in 
combination with LAQ824 were tested in the cell line Hs683. The synergistic 
response is reduced concurrently to the concentrations of 2-DG, meaning that the 
synergism is also dependent of the concentration of 2-DG (Fig. 22A). In a time course 
experiment, the induction of apoptosis by a combination of 2-DG (25mM) and 
LAQ824 (60nM) was analysed by FACS. The single drugs showed almost no loss of 
survival after 72 h treatment whereas the drug combination induced an early cell 
death, observable already after 16 h (Fig. 22B). The detection of PARP cleavage, 
measured by the appearance of the 86 kDa product at 16 h confirmed the strong 
induction of apoptosis which occurred only when both drugs were used together. 
Only weak PARP cleavage was induced by 2-DG but not by LAQ824 after 36h. (Fig 
22C). The data indicate that the two drugs are able to induce cell death by a 
synergistic mechanism.  
 
2-DG dominates LAQ824 when proliferation of Hs683 is inhibited. 
Given the amplified induction of cell death by combined treatment of 2-DG and 
LAQ824, the effect of both drugs on the proliferation of Hs683 was examined. 
LAQ824 affected Hs683 proliferation in a concentration-dependent manner inducing 
an approximate 50% inhibition at the cytotoxic concentration of 180 nM within 72 h 
of drug application, with cells accumulating in G1 phase of the cell cycle (Fig. 
23A,B). Proliferation was reduced more efficiently in a concentration-dependent 
manner under 25 mM 2-DG treatment, whereas low or no cell death was detected at 
this concentration, and cells were accumulating in G2/M phase (Fig. 23B). The 
combined treatment of Hs683 with 25 mM 2-DG and 60 nM LAQ824 exhibited 
essentially the inhibitory effect of 2-DG, which appeared to be dominant over 
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LAQ824. This observation is confirmed by the cell cycle profile where cells, treated 
simultaneously with both drugs, are pushed in G2/M phase after 16 h treatment (Fig. 
23B). Cyclin A levels are drastically reduced upon 2-DG compared to upon LAQ824 
treatment (Fig. 23C).  
 
AKT and ERK are not responsible for the triggering of the synergistic induction 
of apoptosis upon the combination. 
Previous results demonstrated the major role of the kinases AKT and ERK into the 
regulation of the balance between survival and apoptosis, thus, the implication of the 
survival pathway proteins in driving cells into apoptosis was studied. We investigated 
whether AKT and/or ERK are involved in the synergistic induction of cell death in 
glioma cell lines. The phosphorylation of both proteins was analysed following 
treatment by 2-DG and/or LAQ824. 2-DG induced first an increase then a decrease of 
the phosphorylation of Ser473 of AKT (Fig. 24A). 2-DG did not induce 
dephosphorylation of ERK in Hs683. LAQ824 induced a weak decrease of the 
phosphorylation of AKT and an increase of ERK phosphoryaltion after 16 h. The 
levels of phosphorylation of Akt and ERK were both reduced 16h after the addition of 
both drugs around 16 h. At the same time PARP cleavage occurred (Fig. 24B). In the 
same way, the levels of Rad51 were followed over time upon the various treatment 
conditions. The Western-blot indicated that Rad51 decreased similarly to the kinases 
ERK and AKT upon the combined treatment of LAQ824 and 2-DG, consequently to 
the induction of apoptosis (Fig. 24C). 
 
ATP levels, AMPK and S6 phosphorylation are only affected by 2-DG, not by 
the HDIs. 
2-DG is blocking the glycolysis and the ATP production. A drop in ATP levels is 
leading to the activation of the energy sensoring kinase AMPK, whose role is to block 
high energy consuming mechanisms by reducing, for example, the activation of S6K 
and the ribosomal S6 protein which blocks global translation. To determine whether 
the synergistic induction of apoptosis is requires the energy regulatoring pathway, 
ATP levels were first measured in Hs683 after treatment by 2-DG and/or LAQ824. 
Cells exposed to LAQ824 showed similar ATP levels as the untreated cells whereas 
25 mM 2-DG induced a dramatic decrease in the levels of ATP. A similar drop of 
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ATP occurred when the drug combination was used. (Fig. 25A). Phosphorylation 
status and protein levels of AMPK and S6 were determined after exposing Hs683 to 
2-DG and/or LAQ824 for 48 h. In presence of 2-DG, the glycolytic pathway did not 
produce enough ATP resulting in the increase of the AMP/ATP ratio, in the activation 
of AMPK (Fig. 25B) and in the inhibition of the phosphorylation of the downstream 
biomarker S6, whereas LAQ824 did not affect phosphorylation and total levels of 
these proteins. The data suggest that 2-DG inhibits by itself dramatically the energy 
regulatoring pathway and may considerably block translation by strongly decreasing 
phosphorylation of the ribosomal protein S6 (Fig. 25C).  
 
2-DG inhibits the expression of p21 induced by LAQ824 treatment 
Previous studies have demonstrated that expression of the cdk inhibitor p21WAF1/Cip1, 
regulating the progression of the cells from G1 to S phase, causes G1 cell cycle arrest 
and protects cells against the cytotoxic actions of chemotherapeutic agents. In 
addition, many reports have shown that low doses of HDIs were upregulating p21 
expression leading to an accumulation of cells in G1 phase of the cell cycle, whereas 
at high doses, HDIs were cytotoxic. According to these data, the role of p21 in the 
synergistic induction of apoptosis was investigated. First, p21 protein levels were 
followed over 24 h in Hs683 after the addition of 2-DG and/or LAQ824. LAQ824 
increased the expression of p21 in Hs683 after a short time exposure to the drug, 
whereas the presence of 2-DG led to the total disappearance of p21 signal after 4h 
(Fig. 26A). The combination of 2-DG and LAQ824 was tested on glioma cell lines 
and similar effects on p21 levels were observed after 8h exposure to the drugs (Fig. 
26B). Since the overexpression of p21 is responsible for preventing cells to undergo 
apoptosis, it was tested if p21 is still induced at higher concentrations of LAQ824. 
Increasing concentrations of LAQ824 (10, 60, 200, 500, 1000 nM) were applied to 
Hs683 and p21 protein levels were examined after 24 h exposure to the drug. In 
addition, 25 mM of 2-DG was added in order to know whether 2-DG in able to reduce 
p21 at high LAQ824 concentrations. Apoptosis was already detected after 24 h 
exposure to 500 nM and 1000 nM LAQ824 but the expression of p21 protein was still 
induced at high doses (500 nM) (Fig. 26C). The addition of 2-DG at high doses of 
LAQ824 efficiently reduced the levels of p21 protein (Fig. 26C). Therefore, the 
combination of 500 nM LAQ824 and 25 mM 2-DG was tested on Hs683 survival in a 
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time course, similar as in Fig. 22B. The results showed that a synergistic induction of 
apoptosis was also induced at the high dose of LAQ824 in presence of 25 mM 2-DG 
(Fig. 26D). Interestingly, apoptosis was not induced at an earlier time than 16h, 
similar to the lower dose of LAQ824 (60 nM) shown in figure 22B (Fig. 26D). In 
order to test whether p21 protein levels are also reduced at lower 2-DG 
concentrations, increasing doses of 2-DG (1, 5, 7.5, 25 mM) were combined with 60 
nM LAQ824 in Hs683 and western-blot analysis was performed. The levels of p21 
were significantly increased in presence of 60 nM LAQ824 after 8 h but reduced 
when increasing doses of 2-DG were added, even at doses of 2-DG as low as 1mM. 
Phosphorylation levels of S6 were also decreased in a 2-DG concentration-dependent 
manner, 1 mM 2-DG appeared to decrease phosphorylation of S6 and this decrease is 
sufficient to reduce p21 levels in presence of 60 nM LAQ824 (Fig. 26E). Taken 
together, the results suggested that, in parallel to the treatment of HDIs, the decrease 
of the levels of p21 protein after exposure to 2-DG might be involved in the triggering 
of apoptosis.  
 
The synergism between 2-DG and HDIs requires the induction of p21 protein to 
induce apoptosis in Hs683. 
Sequential addition of 2-DG or LAQ824 was tested in order to determine the 
involvement of both drugs in the synergistic induction of apoptosis. First, 60 nM 
LAQ824 was tested in a time course and p21 protein levels of Hs683 were examined. 
The Western analysis showed that the expression of p21 was induced already 4 h after 
the addition of the drug to the cells (Fig 27A). The levels of p21 peak at around 16 h 
and then decrease to reach finally the undetectable basal levels after 48 h (Fig 27A). 
In the first sequential addition of the drugs (Fig 27B), 60 nM LAQ824 were added to 
Hs683 cell culture medium and 2-DG was added either simultaneously (t=0) or after 
LAQ824 at the indicated times (t=16, 24, 36, 48 h). Apoptosis was determined 72h 
after the addition of 2-DG. As control experiments for the use of single drugs, 
apoptosis was measured 72 h after the addition of 2-DG and 72h or 5 days after the 
exposure to LAQ824. The results show that the combination is exhibiting the best 
synergism when 2-DG was added when p21 protein expression induced by LAQ824 
had reached high levels (Fig 27B). Cell death is decreasing proportionally to the 
levels of p21. No synergism is detected anymore when 2-DG is added 48h after the 
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addition of LAQ824 to the cells, that is when p21 expression was back to basal levels 
again.  
In an analogue experiment first 25mM 2-DG was added to the cells followed by 60 
nM LAQ824 at time=0 or after the indicated 16, 24, 36 and 48 h (Fig 27C). Apoptosis 
was determined 72 h after the addition of LAQ824. Again, as controls, apoptosis was 
measured for single drugs after 72 h in the case of LAQ824, and after 72 h and 5 days 
in the case of 2-DG. The results showed that once the cells had been exposed to 2-
DG, strong cell death was induced after 72 h, independently of when LAQ824 was 
added (Fig 27C). 
These results show that, in order to reach a strong synergism, 2-DG has to be 
combined with LAQ824 at time when the levels of p21 protein are high. In contrast, 
LAQ824 can be combined anytime with 25mM 2-DG, since the effect of 2-DG is not 
disappearing with time. The results suggest that high levels of p21 protein are crucial 
for triggering apoptosis, and that such high levels need to be induced by HDIs. 
 
ATP levels play a secondary role in the synergistic induction of apoptosis.  
In order to determine the involvement of energy levels in the synergistic induction of 
apoptosis by 2-DG and LAQ824, pyruvate and other glycolytic inhibitors or blockers 
of ATP utilization were tested in Hs683. First, in order to find out whether the drop of 
ATP levels caused by 2-DG is inducing cell death in presence of LAQ824, pyruvate, 
as another carbon source, was added at an equimolar concentration to glucose to 
allow the production of ATP by passing the block caused by 2-DG. The results 
indicated that pyruvate did not affect the induction of cell death caused by the 
combined drugs (Fig 28A). Also a combination of oligomycin and LAQ824 was 
tested. Oligomycin is known to block the ATP pump in the mitochondria, that is, in 
turn, blocking the use of ATP in the cell without affecting the metabolism of glucose. 
No cell death was observed in Hs683 after 72 h exposure to the single or to the 
combination of drugs (Fig. 28B). No strong change in the p21 protein levels occurred 
after the exposure to the combination, whereas the phosphorylation levels of S6K 
were dramatically reduced (Fig. 28B). The data suggested that the drop of ATP is of 
secondary importance for the synergistic induction of cell death by 2-DG and HDIs.  
In an additional experiment, glucose-free medium was combined with LAQ824 in 
order to block the use of glucose in the cell, mimicking the effect of 2-DG. The 
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results show that glucose withdrawal induces apoptosis and that the presence of 
LAQ824 enhances the induction of apoptosis by 50% (Fig. 28C), suggesting that the 
block of glycosylation processes, active when glucose is metabolized, could be 
involved in the induction of apoptosis upon the synergism. Since both the addition of 
2-DG or glucose withdrawal are affecting glycosylation processes, in contrast to 
oligomycin, the possibility arose that glycosylation could play a role in the synergistic 
induction of apoptosis and that ATP levels are only involved to a limited extent (Fig. 
28A, B).  
We wanted to investigate if the downregulation of p21 protein levels caused by the 
combination of 2-DG and LAQ824 was happening on the translational level. For this 
purpose, RAD001, known to efficiently bring down mTOR activity, was used in order 
to inhibit translation mimicking the effect of 2-DG on p21 levels. However, treatment 
of Hs683 with the combination of LAQ824 and RAD001 did not lead to the 
synergistic induction of apoptosis obtained before by the combination by LAQ824 
and 2-DG although the phosphorylation of S6 was abrogated by RAD001. These 
results suggest that mTOR and S6 are not involved in the synergistic induction of 
apoptosis (Fig 28D). 
 
2-DG and HDIs synergize in other tumor cell lines like HeLa, MCF-7, SKBR-3, 
HBL 
It was investigated whether the synergistic induction of cell death by the combined 
application of the two drugs is also occurring in other cancer cell lines. First, the 
combination was tested on the human cervix cancer cell line HeLa. HeLa cells were 
exposed to increasing doses of LAQ824 (10, 30, 60, 90, 180 nM), in presence or 
absence of 25 mM 2-DG. After 72 h treatment, loss of cell survival was measured by 
FACS. The results showed a strong synergistic induction of apoptosis (Fig. 29A). The 
Western analysis showed that p21 expression increased after treatment with HDI and 
was abrogated in presence of 2-DG as it was the case for the glioma cells. Also the 
phosphorylation of S6 was blocked as a consequence of treatment with 2-DG (Fig. 
29B). To test the efficiency of the combination in other cancer cell lines, MCF7, 
SKBR-3 and HBL were exposed to increasing doses of LAQ824 and 5 mM or 25 mM 
2-DG for 72 h and cell death was measured. These cell lines Also exhibited a 
synergistic induction of cell death by the two drugs (Fig. 29 C, D, E).  
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No synergism is observed in the non-cancer HEK293 and RASMC cell lines, 
even at high HDIs concentrations, except in HSF cell line.  
In order to test the toxicity of the combination on non-cancer cells, the human 
embryonic kidney cell line HEK293 was tested. Interestingly, after 72 h, no cell death 
was induced upon the combination of LAQ824 and 2-DG, even when 2-DG was 
combined with higher concentrations of LAQ824 (Fig. 30A). Since no effect of the 
combination has been detected on the level of cell survival, the drugs have been tested 
on the proliferation of HEK293. The cells have been exposed for 72 h to increasing 
doses of the drugs and the number of cells was determined. The number of cells 
decreased when the doses of LAQ824 and 2-DG were increased (Fig. 30B). The 
results suggest that the drugs are efficiently inhibiting proliferation of HEK293, and 
that the absence of synergism in the induction of cell death was not due to the 
resistance of the cells to these drugs. Other non-cancer cell lines, like RASMC (rat 
aortic smooth muscle cells) and HSF (human skin fibroblast), were then also tested in 
the same way and analysed by FACS. No cell death was induced in RASMC by the 
combination (Fig 30C). However, the synergism could be observed in the HSF cell 
line (Fig 30D) but only at high LAQ824 doses.  
 
Conclusions: The combination of low doses of the glycolytic inhibitor 2-DG and 
HDAC inhibitors is a promising way to efficiently induce apoptosis in glioma and 
other cancer cells whereas no or low toxicity is induced in non-cancer cells. p21 
protein levels seem to play an important role in the mechanism by which apoptosis is 
triggered by the simultaneous inhibition of glycolytic pathway and HDAC. Thus, 
anti-metabolic intervention by 2-DG synergizes with HDIs by blocking re-expression 
of p21 and possibly other critical genes that are silenced. 
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Tumors of the central nervous system (CNS) occur at an incidence of approximately 1 
per 10 000 people, representing 2% of all cancers. However, they account for some 
23% of all pediatric malignancies, ranking second only after leukaemias. 
Furthermore, there has been a reported rise in the incidence of CNS tumors by at least 
one-third over the past 40 years in developed countries (Ohgaki, Dessen et al. 2004). 
Despite this trend which may be due in part to improved imaging, the primary causes 
of human CNS tumors remain hypothetical. Conventional therapies for brain tumors 
currently involve surgical resection together with adjuvant radiotherapy and 
chemotherapy. Despite a proven progress in slightly prolonging mean survival (Stupp, 
Mason et al. 2005), treatment of high-grade tumors remains a compromise between 
control of tumor growth and maintenance of quality of life. 
On one hand, malignant gliomas accumulate many genetic and epigenetic alterations 
in genes involved in regulation of growth, apoptosis and repair. On the other hand, the 
clinical failure of potentially efficient therapeutics might not only be due to a lack of 
drug efficacy, but also to mechanisms of resistance, the heterogeneity in a single 
tumor and the non-liposolubility of the majority of the drugs which impairs or blocks 
the access through blood-brain barrier (BBB). Since chemotherapy and radiotherapy 
for primary brain tumors are non-specific and mostly ineffective, new strategies have 
been developed to overcome the problem of resistance.  
 
The use of specific inhibitors of protein kinases (biologicals) to treat GBMs 
New classes of drugs were designed to specifically target protein kinases: the protein 
kinase inhibitors (PKIs). Some of these drugs also pass the BBB. The efficacy has 
already been demonstrated for AEE788 against human high-grade gliomas (Nathoo, 
Goldlust et al. 2004) or against tumor angiogenesis in mice (Traxler, Allegrini et al. 
2004); for Glivec in chronic myelogenous leukemia (CML) (Capdeville, Buchdunger 
et al. 2002) or for RAD001 against tumor angiogenesis in an animal model (Guba, 
von Breitenbuch et al. 2002), (Chan 2004). The PK targeted by these drugs are 
frequently overexpressed in GBMs by constitutive activation or gene upregulation or 
as results of gain of function mutations in the region encoding the kinase domains. In 
addition, mutation in kinases working downstream in the pathway can occur. 
Regarding the efficiency of these drugs on other cancers and the upregulation of 
EGFR, VEGFR, PDGFR and mTOR in GBMs, we tested AEE788, Glivec and 
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RAD001 on 10 human GBM cell lines in vitro, in order to evaluate the potential of 
these drugs for this highly chemoresistant cancer. The results obtained were 
disappointing. Cell death was not observed at clinically meaningful dose ranges, even 
when the drugs were combined in double and triple combinations. Few cell lines 
responded to these combinations, but only at unspecific high drug doses. In addition, 
the results did not correlate with the known genetic background of the cell lines with 
respect to the tumor suppressor genes encoding p53, p16/p14 and PTEN. Thus, the 
response of the cell lines to the drugs cannot be predicted according to the genetic 
background.  
The resistance we observed in these first results can be due the genetic instability 
which is a hallmark of cancer (Kinzler and Vogelstein 1997; Hanahan and Weinberg 
2000). Indeed, as indicated in the name of the tumor, GBM (glioblastoma multiforme) 
is characterized by marked cytologic and histologic variation and displays extensive 
genetic and biological variability. These characteristics are the main obstacle that 
refrains the efficiency of biologicals in the treatment of GBMs (Hui, Lo et al. 2001). 
During the initial stages of oncogenesis, random alterations that are affecting 
oncogenes and tumor suppressor genes confer growth advantages allowing the 
selection of increasingly aggressive sublines. Thus, GBMs are formed by various 
clones of cells with distinct genetic background. In addition, the cross-talk between 
signaling pathways provide a possible role in chemo-resistance, too. The 
interconnections between distinct signaling cascades can circumvent the inhibition of 
specific protein kinases by alternative pathways. For example, treatment should not 
only consider the ability of RAD001 to inhibit mTOR, but also the inhibition of the 
molecular events downstream of mTOR signaling. 
According to these results, other elements have to be taken into account in order to 
find an effective treatment for GBMs. Indeed, besides the alteration of the activity of 
many protein kinases, GBMs harbor epigenetic alterations (Reifenberger and Collins 
2004) and have an abnormally high glycolytic rate (Gatenby and Gillies 2004) 
compared to normal cells.  
 
Epigenetic alteration: use of histone deacetylase inhibitors 
Genomic alterations activating oncogenes and inactivating tumor suppressor genes 
result in unregulated tumor cell growth are the underlying basis of human tumors 
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(Lund and van Lohuizen 2004). The existing animal models of tumorigenesis, the 
selection of sets of genes contributing to this process and many cancer therapies are 
based on such genomic alterations. In addition, tumor suppressor genes can be 
epigenetically silenced by aberrant methylation and/or histone deacetylation of their 
promoter regions (Merlo, Herman et al. 1995; Baylin and Herman 2000; Hanahan and 
Weinberg 2000; Plumb, Steele et al. 2004). This mechanism of epigenetic regulation 
changes the accessibility of chromatin to the transciption machinery locally via 
modifications of the DNA and histones by modifying or rearranging nucleosomes 
(Momparler 2003). Epigenetic regulation and genetic alterations both collaborate in 
cancer development to act on cell growth and differentiation, cell cycle control, DNA 
repair, angiogenesis, migration, and evasion of host immuno-surveillance. In contrast 
to target the genetic causes of cancers, the possibility of reversing epigenetic changes 
provides new strategies for therapeutic intervention (Plumb, Steele et al. 2004).  
Modulation of gene expression by acetylation and deacetylation of histones is 
allowing or restricting, respectively, the access of the transcriptional machinery on the 
gene promoter (Cress and Seto 2000). The anticancer potential of HDAC inhibitors 
(HDIs) is based on their ability to break several cellular processes that are 
dysregulated in neoplastic cells by restoring the transcription of tumor suppressor 
genes involved in cell cycle regulation, differentiation and proliferation (MacLachlan, 
Sang et al. 1995; Johnstone 2002).  
Since cytotoxic compounds are not well tolerated in patients due to side effects, anti-
cancer drug development has moved from conventional cytotoxic chemotherapeutics 
towards a more mechanism-based targeted approach. Nevertheless, the arrest of the 
proliferation of tumor cells delays growth of the tumor, but does not eradicate tumor 
cells. Regarding the importance of epigenetic alteration in cancer cells including 
GBM cells, in contrast to normal cells, we tested the effect of HDAC inhibitors on 
human glioma cell lines. From the large panel of HDIs currently available, we have 
chosen the two chemicals trichostatin A (TSA) and sodium butyrate (SB). In addition, 
we also tested LAQ824, a new cinnamic hydroxamic acid (Atadja, Gao et al. 2004), 
because this drug is already used in clinical trials for the treatment of leukaemia  
(Nimmanapalli, Fuino et al. 2003; Nimmanapalli, Fuino et al. 2003; Weisberg, Catley 
et al. 2004) and it can pass the BBB. In response to these HDIs, all glioma cell lines 
showed a significant induction of apoptosis in a short time range (72h) (at low 
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micromolar doses for LAQ824). However, low doses of these drugs only weakly 
triggered apoptosis, although a cytostatic effect on glioma cell lines was observed. 
Other cancer cell lines responded much better to these low doses of HDIs. These 
results support the well-known fact that malignant glioma cells are highly resistant. 
Interestingly, when HDIs were tested on the non-cancer cell lines HEK293, RASCM 
and HSF, no cell death could be induced, even at higher doses. These results indicate 
that HDIs are suitable for specifically targeting cancer cells, and suggests that the use 
of HDIs in vivo may only induce low toxicity in the surrounding tissues. 
The mitochondrial cell death pathway is characterized by mitochondrial stress that 
can lead to apoptosome-mediated caspase-9 activation. Caspase-9 activates the 
effector caspases 3 and 7, which then trigger cell death by cleaving selected death 
substrates as PARP, and also process different caspases, thus leading to the generation 
of the pro-apoptotic amplification loop. An alternative extrinsic apoptotic pathway is 
triggered by the cell surface death receptors, which include caspase-8 and caspase-10 
as upstream caspases. By cleaving BID, a Bcl-2 family member, these caspases can 
also induce permeabilization of the mitochondria and activation of the apoptosome 
(Igney and Krammer 2002). Histone deacetylase inhibitors have both pro-apoptotic 
and differentiating effects on tumor cell lines, but the mechanism of action underlying 
the effects of HDIs remains unclear. Some recent studies done in this purpose are 
contradictory and show some discrepancies. For example, the studies done by Komata 
and colleagues on glioma cell lines showed that HDI-induced apoptosis by sodium 
butyrate and trichostatin A (TSA) was caspase-dependent, involving caspase-8 but 
not caspase-9 (Komata, Kanzawa et al. 2005). This suggested that HDI-induced 
apoptosis was not mediated by the mitochondrial cell death pathway, also because no 
change in the mitochondrial membrane potential could be detected (Komata, 
Kanzawa et al. 2005). However, in another report, Henderson and colleagues showed 
that caspase-9 is critical for apoptosis induced by the HDI suberoylanilide 
hydroxamic acid (SAHA) and TSA and that efficient proteolytic activation of 
caspase-2, caspase-8, and caspase-7 strictly depends on caspase-9 (Henderson, 
Mizzau et al. 2003). They showed that SAHA and TSA induced translocation of BID 
into the mitochondria and cytochrome c release. They also claimed that the 
susceptibility to TSA- and SAHA-induced cell death is regulated by p53, whereas 
other studies demonstrated the opposite and identified the death receptor pathway 
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(Insinga, Monestiroli et al. 2005) as an alternative apoptotic pathway activated by 
HDIs. 
 
Inhibition of glycolysis 
Energy production represents an interesting pathway to be targeted in GBMs. Indeed, 
tumor cells have abnormal mitochondrial function and essentially rely upon 
glycolysis to provide ATP for their metabolic requirements. This means that GBM 
cells have a low oxygen demand and can survive in an environment with low oxygen 
concentrations that would not be suitable for normal cells. Glycolysis is an 
evolutionary ancient metabolic pathway found in all cells that enables organisms to 
provide energy for biological processes, by the oxidation of glucose without the 
requirement of oxygen (Gatenby and Gillies 2004). Human GBMs are much more 
avid of glucose than normal cortex cells, since high glucose consumption was 
demonstrated by FDG-PET in these tumors (Annex 4) (Novak, Molnar et al. 2005). 
The glycolytic inhibitor 2-deoyxy-D-glucose (2-DG) efficiently inhibits glycolysis by 
blocking the access of glucose to the hexokinase (Kaplan, Navon et al. 1990). 2-DG 
itself is not metabolized but acts as a competitive inhibitor of glucose for hexokinase 
(Gallagher, Fowler et al. 1978). The anticancer effect of 2-DG has been demonstrated 
in combination with radiotherapy (Mohanti, Rath et al. 1996; Dwarkanath, Zolzer et 
al. 2001) for the treatment of human GBMs. 2-DG inhibits repair of radiation-based 
DNA damage by depleting energy levels leading to an enhancement of apoptosis. 
Used as a single agent, 2-DG reduces in vivo the size of liver tumors in rats (Cay, 
Radnell et al. 1992) and induces apoptosis in vitro in breast cancer cells by inducing 
cytochrome c release and PARP cleavage (Aft, Zhang et al. 2002). 
We tested the effect of 2-DG on human GBM cell lines in vitro. The results showed 
that 2-DG was able to induce apoptosis in all GBM cell lines after 72 h of treatment, 
but only at high concentrations (equimolar with 25 mM glucose, or at 100 mM), 
whereas no apoptosis was induced at lower doses of 2-DG such as 1 mM or 5 mM 
after 72 h of exposure. Nevertheless, 2-DG was able to efficiently inhibit proliferation 
of all glioma cell lines at these lower doses that are suitable for clinical application. 
Interestingly, PTEN mutant cell lines exhibited a weaker sensitivity to 2-DG 
compared to the PTEN wild-type cell lines with regard to induction of cell death. 
Compared to other cancer cell lines, glioma cell lines exhibited lower cell death upon 
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2-DG treatment, whereas no cell death was induced in the non-cancer cell lines 
HEK293, HSF and RASMC, even at very high doses of 2-DG (100mM). Of note 
glucose withdrawal induced earlier and stronger apoptosis in glioma cell lines in 
contrast to 2-DG. Upon glucose withdrawal, cellular ATP is quickly used up. 
However, the addition of pyruvate (source of ATP) to the medium of the cells does 
not rescue significantly cell survival. In the case of an addition of 2-DG, glucose is 
still present, but the competitive inhibition of hexokinase activity by 2-DG might alter 
the normal use of glucose in the cell. This may explain why ATP depletion is faster 
following 2-DG addition than upon glucose withdrawal. The decrease of ATP is not 
correlated with cell death induction. Indeed, although ATP levels drop much more 
following 25 or 100 mM 2-DG than upon glucose withdrawal, cell death is induced 
earlier and more intensively by glucose starvation than upon 2-DG treatment. In 
consequence, we propose that 2-DG and glucose starvation induce cell death through 
different mechanisms, although both are inducing cytochrome c release and PARP 
cleavage.  
Induction of cell death by energy depletion remains poorly understood. Since glucose 
is the major source for the process of glycosylation, the glycosylation of essential 
proteins like transcription factors might also be profoundly affected in the absence of 
glucose (Han and Kudlow 1997) or by blocking glucose usage by 2-DG treatment 
(Kang, Ju et al. 2003). This may explain why pyruvate cannot restore survival in cells 
treated with high doses of 2-DG. Some studies on c-Myc have suggested a role of this 
oncogene in the induction of cell death by energy depletion. For example, prolonged 
culture of pancreatic beta-cells in low-glucose concentrations increased c-myc 
expression and induces caspase-dependent apoptosis (Van de Casteele, Kefas et al. 
2003). Shim and colleagues observed that glucose deprivation or treatment with 2-DG 
caused arrest in the G0/G1 phase of the cell cycle of non-transformed cells. However, 
c-Myc-transformed fibroblasts, lymphoblastoid, or lung carcinoma cells underwent 
extensive apoptosis (Shim, Chun et al. 1998). These observations are providing 
insights into the coupling of glucose metabolism and apoptosis. In addition, c-Myc 
has been shown to be overexpressed in GBMs (Orian, Vasilopoulos et al. 1992). 
Thus, c-Myc could be the missing link between energy depletion and apoptosis in 2-
DG-treated glioma cell lines.  
Another interesting observation is that 2-DG is able to efficiently reduce the levels of 
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the repair protein Rad51. Clinically, the radiosensitivity of tumor cells after exposure 
to 2-DG in human patients (Dwarkanath, Zolzer et al. 2001) can be explained by the 
reduction in the levels of Rad51 protein (Russell, Brady et al. 2003). Indeed, 
radiotherapy induces various DNA lesions, including double strand breaks, in 
dividing cells. Repair of radiation-induced damages requires continuous supply of 
energy. In presence of 2-DG, the decrease of Rad51 protein levels may be the 
consequence of the inhibition of transcription and/or translation. Since Rad51, and 
probably other repair proteins play an essential role in the repair of radiation-induced 
damage and induction of cell death, cells that cannot recover from the damage will 
undergo cell death. Nevertheless, clinically applicable doses of 2-DG (1 and 5 mM) 
induced only a block of proliferation of GBM cell lines, but could not induce cell 
death. 
 
Our initial observations indicated that GBM cells are resistant to “biologicals” which 
include specific targeting of essential kinases of pathways involved in the 
development and maintenance of the disease: mTOR, PDGFR, EGFR and VEGFR. 
Even upon the combination of RAD001, Glivec and AEE788, cell death was not 
increased in vitro in dose ranges suitable for clinical application. The glycolytic 
inhibitor 2-DG could induce apoptosis in glioma cell lines, but only at high doses (25 
and 100mM), which could not be achieved in human patients. Serum concentration up 
to 7mM have been reported, corresponding to an administration of 200mg/kg body 
weight (Mohanti, Rath et al. 1996). Even the HDIs like TSA, SB, SAHA and 
LAQ824 could not trigger strong apoptosis in glioma cell lines at low nanomolar 
range. Nevertheless, an inhibitory effect on the proliferation of the GBM cells was 
observed at low doses for these drugs, which would be suitable for a clinical 
application. However, since the inhibition of proliferation of all cytostatic drugs is 
generally disappearing once the treatment is stopped, the only way to get rid of cancer 
cells is to induce cell death. From these disappointing results arose a new strategy 
where drugs from various classes (“biologicals”, “cytotoxics”, glycolytic inhibitors, 
NSAIDs) are combined with each other in order to trigger synergistically apoptosis or 
to induce additive tumor cell death.  
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Simultaneous inhibition of mTOR by RAD001 and glycolysis by 2-DG. 
The previous observations on RAD001 raise the possibility to use this drug as a 
“sensitizer” in order to enhance 2-DG-induced apoptosis at clinically applicable doses 
like 1 mM or 5 mM. We have proposed that RAD001 could be able to sensitize the 
AKT/mTOR signaling pathway to apoptosis induced after 2-DG treatment, since the 
PTEN-mutant GBM cells are more sensitive to RAD001. Previous studies have 
already shown potentiation in the inhibition of tumor growth or in the induction of 
apoptosis, when rapamycin derivatives are combined with cytotoxic agents 
(Mondesire, Jian et al. 2004), cisplatin (Geoerger, Kerr et al. 2001; Beuvink, Boulay 
et al. 2005) or AEE788 (Goudar, Shi et al. 2005). Since 2-DG is acting as a cytotoxic 
agent by inducing apoptosis at high doses and as a cytostatic agent at low doses, the 
combined application of low 2-DG and RAD001 was tested on GBM cells. The 
results show a negative effect of the combination in the induction of apoptosis in all 
human GBM cell lines. The level of apoptosis was delayed by about 30 to 50% 
depending on the cell line. This negative effect was reproducible when RAD001 was 
combined with glucose withdrawal, independently of the PTEN status.  
The antagonistic effect in the induction of apoptosis is not understood yet, since 
neither ERK nor AKT appeared to be involved in this mechanism. RAD001 is mainly 
downregulating translation downstream of mTOR, whereas 2-DG is mainly affecting 
ATP production and protein glycosylation (Kang, Ju et al. 2003). It can be that upon 
blocking glycolysis, other mechanisms can be promoted as autophagy to provide 
energy to the cell. Autophagy is defined as the degradation of cellular proteins in 
response to nutrient deprivation or other types of stresses in order to allow ATP 
production (Klionsky and Emr 2000). mTOR has profound effects on the control of 
apoptosis and autophagy (Castedo, Ferri et al. 2002). Rapamycin has been found to 
induce autophagy rather than apoptosis in yeast and cultured mammalian cells, such 
as hepatocytes (Shigemitsu, Tsujishita et al. 1999). Rapamycin was found to induce 
autophagy in glioma cell lines whereas no induction of cell death could be observed 
(Takeuchi, Kondo et al. 2005). The delay in apoptosis observed upon the combination 
of 2-DG and RAD001 could be due to the induction of autophagy by RAD001 which 
would reduce 2-DG-induced cell death by providing more ATP. However, the 
stimulation of autophagy by mTOR inhibitors is not well defined.  
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mTOR plays a central role in the regulation of apoptosis. This has been demonstrated 
by the sensitization of tumor cells to cytotoxic agents by rapamycin (Beuvink, Boulay 
et al. 2005). Rapamycin has been reported to selectively kill mouse embryo 
fibroblasts deficient either in p53 or in p21 (Huang, Liu et al. 2001). The inhibition of 
apoptosis by mTOR can be due to the phosphorylation of BAD by S6K, a reaction 
that disrupts the binding of BAD to the mitochondrial death inhibitors Bcl-2 and Bcl-
XL and thus inactivates BAD (Harada, Andersen et al. 2001). In contrast, the 
induction of apoptosis by mTOR was suggested by the combination of rapamycin 
with taxol, in which rapamycin could inhibit the taxol-induced cell death of human B-
cell lines correlating with a dephosphorylation/deactivation of Bcl-2, whereas taxol 
induces phosphorylation of Bcl-2, activating apoptosis. In this report, it was found 
that mTOR was activated in cells treated with taxol although it was inhibited in cells 
pre-treated with rapamycin (Calastretti, Bevilacqua et al. 2001). Rapamycin inhibits 
the phosphorylation of p53 resulting in its transcriptional activation that induces pro-
apoptotic proteins such as Bax and subsequent apoptosis (Castedo, Ferri et al. 2001). 
In order to answer the question by which RAD001 delays apoptosis induced by 2-DG, 
several additional experiments have to be done in order to determine whether some of 
these pro-apoptotic (Bax, BAD) or pro-survival proteins (Bcl-2, Bcl-xl) are 
deactivated or activated in the presence of RAD001. 
In contrast to RAD001 plus 2-DG, the combination of 2-DG and LY enhanced cell 
death in LN401 GBM cells. Inhibition of the PI3K/AKT pathway by LY sensitized 
the cells to 2-DG-induced apoptosis. A broader study has to be done in other glioma 
cell lines in order to define the extent and the limitation of this combination, for 
example, it would be interesting to know whether this combination depends on the 
PTEN status since PTEN-mutant cells exhibit a stronger activation of the PI3K/AKT 
pathway than wild-type cells. 
 
Simultaneous inhibition of histone deacetylases and glycolysis 
Previous reports have already shown interesting effects on cancer treatment when 
HDACs inhibitors (HDIs) were combined with other drugs. For example, in acute 
promyelocytic leukemia with t(11;17)/PLZF-RAR translocation, a combination of 
all-trans retinoic acid with the HDI trichostatin A resulted in differentiation of all-
trans retinoic acid-resistant acute promyelocytic leukemia cells (Ferrara, Fazi et al. 
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2001). An important finding in predicting the potential utility of HDIs in the clinic is 
their activity in cell lines that are resistant to existing chemotherapeutics. For 
example, Glivec-resistant Bcr/Abl human chronic myelogenous leukaemia (CML) 
cells are sensitized to Gleevec upon co-treatment with SAHA (Yu, Rahmani et al. 
2003). In addition, CD34-positive progenitor cells from patients with Gleevec 
refractory CML respond to SAHA treatment and exhibit increased apoptosis and 
histone acetylation levels (Nimmanapalli, Fuino et al. 2003). In other studies, 
combinations of HDIs with other drugs such as the PI3K inhibitor LY294002 
(Rahmani, Yu et al. 2003), the ATM inhibitor caffeine (Burgess, Ruefli et al. 2004) or 
DNA damaging agents (Kim, Blake et al. 2003) showed synergistic effect with 
respect to induction of cell death. We exploited new approaches for the treatment of 
GBMs, focusing on a combination of drugs that restores gene expression via 
inhibition of HDACs and glycolysis. 
 
In order to enhance the efficiency of HDIs to induce apoptosis and according to the 
ease of these drugs to synergize with other drugs, we tested, in vitro, the combination 
of HDIs and the glycolytic inhibitor 2-DG on human GBM cells. The question was 
whether low concentrations of HDIs with reduced toxicity, would potentiate apoptosis 
when used in combination with 2-DG. It is already known that 2-DG as well as HDIs 
like SAHA, butyrates (NaB) or LAQ824 are well tolerated in patients and are able to 
pass the BBB. We found that 2-DG strongly increases HDI-induced apoptosis in all 
human GBM cells tested in a p53-independent manner, as Hs683, LN401, LN229 and 
U373 are mutated for TP53 (Ishii, Maier et al. 1999). The cells exposed to this 
combination exhibited 95% cell death whereas only basal levels of apoptosis were 
detected after the exposure to the single drugs at concentrations with reduced toxicity. 
Of note is the finding that this synergism is specifically efficient in cancer cells 
whereas no cell death could be induced in non-cancer cells, even at high HDI doses 
(except in HSF).  
Among 2% of genes that are targeted by HDIs, the up-regulated expression of the 
cyclin-dependent kinase inhibitor p21 is responsible for the anti-proliferative effect of 
the drug  (Richon, Sandhoff et al. 2000; Blagosklonny, Robey et al. 2002). A number 
of studies have demonstrated that expression of p21 causes a G1 cell cycle arrest and 
protect cells against chemotherapeutic agents (Fueyo, Gomez-Manzano et al. 1998; 
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Burgess, Pavey et al. 2001; Schmidt and Fan 2001). Among cells that have HDI-
induced p21 expression, only cells in late G1 and S phase proceed through an aberrant 
mitosis and rapid apoptosis, whereas cells in G1 phase accumulated p21 and arrest. 
We have shown that, at low doses, HDIs only induced weak cell death that did not 
increase with time, whereas at higher doses, HDIs could induce significant cell death. 
The expression of p21 was observed at low as well as at high concentrations and 
peaks around 8 to16h and declines to almost control levels by 36h to 48h. After HDI 
treatment, the cells still undergo apoptosis later on which can be due to the decrease 
of the levels of p21 protein. If p21 is protecting cells against the induction of 
apoptosis, a decrease of p21 would allow the process of apoptosis. Our results showed 
that the HDIs TSA, NaB or LAQ824 all induced an increase in p21 protein levels 
after 8h treatment, and that this resulting p21 upregulation is abrogated in presence of 
the glycolytic inhibitor 2-DG. Sequential addition of HDI and 2-DG demonstrated 
that the expression of p21 needs to be induced in order to synergistically trigger 
apoptosis by this combination. Indeed, if 2-DG is added when p21 levels are low, no 
synergism was induced and no cell death observed. The effect of HDIs on p21 is 
transient whereas the inhibitory effect of 2-DG on glycolysis is lasting. We also 
observed that the decrease of the basal levels of p21 by 2-DG without HDIs treatment 
did not induce apoptosis. These results suggest that the inhibition of p21 upregulation 
upon HDIs by 2-DG is triggering apoptosis. However, many other factors might be 
involved in the synergism. Indeed, the exposure of cells to HDIs not only upregulates 
the expression of p21, but also concurrently activates other pathways which may be 
involved in the induction of apoptosis. On one hand, these pathways are inducing 
apoptosis, on the other hand, p21 upregulation is protecting cells against the 
activation of these pathways by blocking fundamental steps. The anti-apoptotic effect 
of p21 may be the result of a number of mechanisms. For example, p21 has been 
demonstrated to bind to procaspase-3, the inactive form of caspase-3, responsible for 
apoptosis triggering, and inhibits its proteolytic activation (Suzuki, Tsutomi et al. 
1999). Procaspase-3/p21 complexes have been found in the mitochondria to resist 
Fas-mediated cell death in HepG2 cells (Suzuki, Tsutomi et al. 1999). In turn, 
caspase-3 contains p21-binding domain in the N-terminus, independent of the PCNA-
binding site; p21 is also a substrate for caspase-3 cleavage, producing 14 and 7 kDa 
fragments (Gervais, Seth et al. 1998). Caspase-3 is cleaving other executioners 
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including PARP. The expression of p21 has also been reported to induce the 
expression of anti-apoptotic factors (Chang, Watanabe et al. 2000). HDIs are inducing 
the expression of pro-apoptotic factors like Bcl-2 (Facchetti, Previdi et al. 2004) 
which would trigger apoptosis via the mitochondrial pathway. An alternative to the 2-
DG/HDIs-mediated apoptosis would be the extrinsic pathway triggered via the death 
receptors, since HDIs have been reported to induce the expression of the ligand for 
death receptor, trail (Nebbioso, Clarke et al. 2005). However, whether this pathway 
can be activated in glioma cell lines remains unclear (Nebbioso, Clarke et al. 2005). 
Some additional experiments have to be done in order to find out how apoptosis is 
triggered by this synergism. For example, we could determine whether cytochrome c 
is released by this combination, this experiment will tell us whether cell death is 
mediated via the mitochrondria pathway. 
The main question remains, by which mechanisms 2-DG abrogates levels of p21. 
Either 2-DG affects the transcription of p21, or the translation of p21, or both. In our 
studies, we showed that RAD001 only weakly inhibited p21 upregulation induced by 
HDI and, in addition, no real synergism was observed when RAD001 and HDIs were 
combined, even when the concentration of RAD001 applied was ten times higher of 
its IC50 value to fully inhibit the mTOR pathway. The protein levels showed that 
RAD001 was not able to strongly reduce p21 levels. A drop of ATP is activating 
AMPK which in turn inhibits mTOR, S6 and 4EBP1 phosphorylation and finally 
ribosome biogenesis. The effect of 2-DG is comparable to the effect of RAD001. In 
our results, the addition of pyruvate in the combination of 2-DG and LAQ824, which 
allows production of ATP, does not affect the synergism. The combination of the 
inhibitor of the ATP-pump oligomycin with HDIs is not inducing cell death, whereas 
the combined treatment of HDIs and glucose withdrawal induced a comparable 
synergism comparable to this one induced by HDIs and 2-DG. These results suggest 
that the inhibition of translation could be responsible to a limited extent in the 
abrogation of p21 levels and that other mechanisms may also be involved in this 
synergism. 
Previous studies support the hypothesis that 2-DG strongly reduced p21 levels at the 
transcriptional level. Indeed, the p21WAF1 promoter is controlled by p53 and/or Sp1 
transcription factors. Since we showed that p21 is still up-regulated upon HDIs 
treatment in p53 mutant cells, Sp1 appears to be the most important transcription 
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factor regulating p21 transcription. Kang et al (Kang, Ju et al. 2003) investigated how 
2-DG and low glucose are affecting transcriptional activity of Sp1. They could show 
that poor ATP generation is involved only to a limited extent since gene transcription 
was only marginally affected by the inhibition of ATP synthesis. However, Sp1 is one 
of the nuclear proteins that are glycosylated at serine/threonine residues by N-
acetylglucosamine (GlcNAc) through O-GlcNAcylation. Many key proteins within 
the cytoplasm and nucleus are now known to be glycosylated, including proteins of 
diverse functional groups: kinases, phosphatases, cytoskeletal proteins, chaperones, 
metabolic enzymes and transcription factors such as Sp1. Jackson et al. showed for 
the first time in 1988 that the human RNA polymerase II transcription factor Sp1 
bears multiple O-linked N-acetylglucosamine monosaccharide residues and that these 
residues may play a role in the mechanism or regulation of transcriptional activation 
of RNA polymerase II (Jackson and Tjian 1988). The modification of proteins by O-
linked-β-N-acetylglucosamine (O-GlcNAc) is modulating cellular function in 
response to nutrition and stress. O-GlcNAc is acting in a manner analogous to protein 
phosphorylation (Schafer, Hamm-Kunzelmann et al. 1997). O-GlcNAc levels respond 
to mitogens, cellular signals, growth factors and modulate enzyme activity or 
regulation, protein-protein interaction, DNA binding, subcellular localization and the 
half life and proteolytic processing of proteins. Nevertheless, the way that O-GlcNAc 
is mediating its effects remains unclear. The addition and removal of O-GlcNAc is 
achieved by two enzymes: the O-β-N-acetylglucosaminyltransferase (OGT) and the 
O-linked-β-N-acetylglucosaminidase (O-GlcNAcase). Kang et al showed that 2-DG 
down-regulates Sp1 activity through hyper-GlcNAcylation, by affecting these 
enzymes, but the mechanism is not defined yet (Kang, Ju et al. 2003). In this regard, 
the finding that RAD001, an inhibitor of mTOR and by extension, S6, failed to 
enhance HDI lethality argues against a critical role for this pathway in the synergism 
and suggests the main intervention of the inhibition of Sp1 by hyperglycosylation and 
further on the inhibition of p21 transcription. Indeed, they show that 2-DG induced an 
early hyperglycosylation of Sp1, within 4 hours treatment upon 25mM 2-DG, 
responsible for the simultaneous decrease of p21 protein levels. This is correlated 
with our results showing that 2-DG reduces early p21 levels (also around four hours) 
in Hs683. 
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These findings indicate that other combinations of drugs can induce similar synergism 
regarding the implication of p21 proteins in the regulation of cell survival. First, 
important is that p21 is not mutated in GBMs (Tsumanuma, Tanaka et al. 1997). 
However, our results show p21 reexpression after treatment with HDIs. Second, many 
reports have demonstrated the pro-survival effect of p21 upon chemotherapeutic 
treatments. These facts suggest that any cytotoxic drug, that is increasing p21 levels, 
independently of p53 or not, can be combined with any agent that is strongly 
inhibiting p21 upregulation, as 2-DG. Several reports are supporting this hypothesis. 
Lane and colleagues (Beuvink, Boulay et al. 2005) have tested the combination 
composed by cisplatin and RAD001 on breast cancer cell lines in vitro. In this study, 
the cytotoxic agent cisplatin was upregulating p21 protein whereas RAD001 
simultaneously induced a decrease of p21, synergistically induced apoptosis. In 
another study, sodium butyrate (SB) also synergized with the PI3K inhibitor 
LY294002 (Rahmani, Yu et al. 2003), inducing strong cell death consequently to p21 
downregulation. Burgess and colleagues showed that the ATM inhibitor caffeine 
(Burgess, Ruefli et al. 2004) also abrogated p21 expression when combined with the 
HDI, suberic bishydroxamic acid (SBHA) leading to a synergistic induction of 
apoptosis. The mechanism by which the combination of 2-DG with HDIs is 
synergistically inducing apoptosis in glioma cell lines remains to be defined. Thus, we 
propose one possible model to explain the complexity of the mechanisms involved 
into the synergism (Fig. 31).  
 
The combination of HDIs with the NSAID Indomethacin (IND)  
In a similar way, since GBMs overexpress COX-2, the inhibition of HDACs was 
combined with indomethacin (IND), an inhibitor of cyclo-oxygenases. Our results 
showed an interesting synergism between the HDI LAQ824 and indomethacin on 
inducing apoptosis in human GBMs, whereas no effect was observed in the normal 
HEK293, RASMC or HSF cell lines. In addition, the results concerning protein 
analysis in HS683 upon the combination, suggests that p21 could, again, be involved 
in the synergistic induction of apoptosis. Nevertheless, additional experiments have to 
be done in order to understand the mechanisms underlying the effects observed on 
cell survival. 
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Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and 
ibuprofen are the most widely used drugs for pain, arthritis (Schuna 1998), (Curtiss 
2002), cardiovascular diseases (Goodnight 1996), the prevention of colon cancer 
(Sheng, Shao et al. 1997) and Alzheimer disease (Sloane 1998). However, NSAIDs 
produce gastroduodenal ulcers in about 25% of users (often with bleeding and/or 
perforations) and delay ulcer healing, presumably by blocking prostaglandin synthesis 
from cyclooxygenase COX-1 and COX-2. Other adverse effects have been noticed on 
the blood pressure and renal function. The hypothesis that the gastrointestinal side 
effects of NSAIDs result from inhibition of COX-1, but not COX-2, led to the 
development of NSAIDs that selectively inhibit only COX-2 (such as celecoxib and 
rofecoxib). Jones and colleagues showed that both COX-1 and COX-2 are important 
for angiogenesis and these findings challenge the premise that selective COX-2 
inhibitors will not affect the gastrointestinal tract, ulcer and wound healing (Jones, 
Wang et al. 1999). Large-scale clinical out-come studies showed reductions in the 
range of 50% in clinical gastrointestinal events with COX-2 inhibitors compared with 
non-selective NSAIDs among patients not taking aspirin. Overall, the results indicate 
an advantage for cox inhibitors, but that their use is not devoid of serious 
gastrointestinal adverse events. (Laine, Connors et al. 2003).  
 
Orthotopic glioma rat model  
In vitro assays allow to quickly determine the impact of a drug according to the 
genetic background. Considering that each cell line displays a specific combination of 
genetic defects, altogether they may represent the heterogeneous nature of GBMs, and 
the efficacy of the drug on a number of those could statistically mimic the potential 
effect of this drug in an in vivo model. Although xenograft studies are not fully 
predictive of the therapeutic efficacy of cancer therapies in clinical trials, xenograft 
studies may offer additional information over cell culture studies. These in vitro 
experiments are necessary since they allow to characterize the specific effects of this 
compound on its biomarker(s), on cell-cycle and cell survival.  
Development of an orthotopic GBM rat models will further enable us to determine 
whether the synergism induced by the combinations of HDIs with 2-DG or with 
indomethacin, or a COX inhibitor, able to pass the BBB, can be reproduced in vivo. 
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These models will also give use some clues about their potential toxicity. These data 
are necessary prior to the introduction of the combinations into clinical studies.  
 
Clinical relevance of the work 
Our results show that the combination of HDAC inhibitors with 2-DG or with 
indomethacin are only inducing apoptosis in cancer cell lines whereas no cell death 
was observed in the non-cancer cell lines. Of importance is that the synergism is 
operating on the level of apoptosis and not only on the level of cell growth, which is 
more promising with respect to disease remission. 
Clinically, 2-DG and indomethacin (and analogues) are well tolerated in humans and 
pass the blood-brain-barrier. HDIs may be more toxic in human application. 
However, since low doses of HDIs are sufficient to reach a strong synergism in 
presence of 2-DG, the combination of drugs is welcome in clinical trials for the 
treatment of GBMs. In addition, since we showed that other cancer cell lines 
exhibited similar synergism upon both combinations, we can conclude that they could 
be an attractive treatment for various solid cancers.  
 
In this work we demonstrated that GBMs show high resistance to in vitro treatments 
that target individual pathways like the “biologicals” RAD001, AEE788 and Glivec 
but also to “cytotoxics” HDAC inhibitors (HDIs) and EPO906A at doses applicable in 
clinics. We have exploited new approaches in the treatment of GBMs by combining 
the anti-metabolite 2-DG with HDIs at doses of reduced toxicity, where synergistic 
effects were observed in 100% of the glioma and other cancer cell lines tested, but not 
in non-cancer cell lines. Thus, anti-metabolic intervention combined with HDIs might 
be a promising treatment for solid cancers. Our results and previous reports support 
the hypothesis that the simultaneous combination of agents that increase p21 
expression (such as HDIs) with agents that abrogate p21 upregulation (such as 2-DG), 
might be good choice for the treatment of GBMs. The data obtained upon the 
treatment of 2-DG also suggest that future clinical trials designed for the treatment of 
GBMs must take into account the inhibition of the glycolytic pathway. Nevertheless, 
significant challenges remain for the development of drug combinations to treat 
GBMs, namely the inability to predict tumor response and genetic instability that may 
allow cells to escape from pro-apoptotic stimuli. 
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Precursors of CNS tumors 
 
In the central nervous system (CNS), multipotent neural stem cells in the 
ventricular/subventricular zones of the embryonic neural tube give rise to three main 
cell types in the mature CNS: neurons, oligodendrocytes and astrocytes. It is 
suggested that that neural stem cells first differentiate into two distinct progenitor 
cells: neuronal restricted progenitor cells and glial restricted progenitor cells, which 
further differentiate into neurons and glia, respectively. 
Several genetic pathways are involved in the initiation and in the progression of 
secondary GBMs. Loss of p53 and activation of growth-factor-RTK-RAS pathway or 
loss of NF1 are involved in the initiation of grade 1 and grade II astrocytoma. These 
can progress to grade IV GBM after disruption of RB pathway. In primary GBM, the 
same genetic pathways are dismantled, through different mechanisms. Amplification 
and/or mutation of EGFR is often detected and PTEN phosphatase activity is 
frequently disrupted.  
Neuronal-restricted
progenitor cells
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Glial-restricted
progenitor cells
Neurons Medulloblastoma
Oligodendrocytes
Oligodendroglioma
Astrocytes Secondary  GBM
(grade IV)
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astrocytoma
(grade III)
Pilocytic  astrocytoma
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Progression pathway
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Primary GBM
(grade IV)
INK4A loss, EGFR amplification/mutation
PTEN loss, MDM2 amplification 
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Maher et al, Genes and Development,Vol 15, 2001 
 
 
 
 
 
 
 
 
 
 
Two pathways to GBMs 
 
GBM can develop over 5-10 years from a low-grade astrocytoma (secondary GBM), 
or can be the initial pathology at diagnosis (primary GBM). The clinical features of 
GBM are the same regardless of clinical routes. 
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Blood vessel co-option precedes angiogenesis in astrocytoma progression.  
 
Astrocytomas first acquire their blood supply by co-opting existing normal brain 
blood vessels without the necessity to initiate angiogenesis.  
 
A. They instead grow along blood vessels, without a tumour capsule, eliciting an 
invasive character.   
B. When grade III astrocytomas progress into glioblastomas (GBM or grade IV 
astrocytoma), they become hypoxic and necrotic — partly due to vessel regression 
and increased tumour-cell proliferation. C.These conditions, in turn, induce formation 
of new blood vessels (angiogenic sprouting) that supply the tumour with the 
necessary metabolites. In fact, glioblastomas are partly defined by the appearance of 
proliferating endothelial cells and a high blood-vessel density that distinguishes grade 
IV tumours from the lower-grade astrocytoma 
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     Neurosurgical University Clinic, Basel 
 
The glucose analog tracer 18fluoro-deoxy-glucose is used in humans for PET 
imaging 
 
Malignant glial brain tumors display a high consumption of glucose, even more than 
the cells from the cortex. Malignant transformation is usually manifested by an 
increase of 18 fluorodeoxyglucose (FDG) uptake which is not metabolized. 
(A): MRI: Magnetic resonance imaging: shows a large thalamic GBM on the left side. 
MRI is commonly used to determine the location and extent of cerebral GBMs. 
(B): FDG-PET (positron emission tomography). Metabolic imaging using an 
analogue of glucose. Note the increased 18FDG uptake in the tumor compared to 
normal cortex. 
(Novak, Molnar et al. 2005) 
brain tumor 
A 
B 
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Gatenby et al, Nature Review Cancer, Vol 4, Nov 2004  
 
 
 
 
 
 
 
 
Glucose metabolism in mammalian cells.  
 
Blood delivers glucose and oxygen (on haemoglobin) to tissues, where it reaches cells 
by diffusion. Glucose is taken up by specific transporters, where it is converted first to 
glucose-6-phosphate by hexokinase and then to pyruvate, generating 2 ATP per 
glucose. In the presence of oxygen, pyruvate is oxidized to HCO3, generating 36 
additional ATP per glucose. In the absence of oxygen, pyruvate is reduced to lactate, 
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which is exported from the cell.  
Annex 6 
 
 
 
 
 
 
 
 
 
 
 
Tight junction    L. L. Rubin et al, Annu. Rev. Neurosci. 1999. 
Adherent junction 
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Misra et al, J Pharm Pharmaceut Sci, Aug 2003 
 
Structure of the Blood-Brain Barrier. 
 
The BBB is an endothelial barrier present in capillaries that course through the brain. 
Brain capillary endothelial cells (ECs) are coupled by adherent and tight junctions 
limiting paracellular flux. P-glycoprotein is expressed in the apical membrane of the 
EC and actively ejects certain undesired substances from the central nervous system 
(CNS). ECs have very few endocytotic vesicles limiting transcellular flux. 
Transcytosis across brain ECs occurs slowly, minimizing transcellular movement into 
the CNS. The cell closest to brain capillary ECs is the astrocyte, whose endfeet cover 
the capillary’s basal surface, although an extracellular matrix is interposed and may 
release molecules that influence their phenotype. Not shown are the transporters for 
essential nutrients, such as glucose and amino acids, and for macromolecules such as 
transferrin. 
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Targeting mitogenic pathways in gliomas.  
 
Several growth-factor pathways are inappropriately activated in gliomas through 
overexpression, amplification or activating mutations, including EGFR and PDGFR 
that induce the activation of numerous downstream signal transduction pathways that 
regulate gene transcription, translation or cell cycle. In addition, tumor suppressor 
genes are frequently inactivated through deletion, mutation or promoter silencing. 
 
Several proteins in these cascades are the targets of therapies in development for 
malignant gliomas, like mTOR, PDGFR, EGFR, histone deacetylases (HDAC) and 
tubulin for microtubule dynamics. The glycolytic inhibitor 2-DG is targeting 
Hexokinase II (HKII). The drugs are indicated in red. 
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Chromatin structure regulates transcriptional activity.  
 
Nucleosomes consist of DNA (black line) wrapped around histone octomers (purple). 
Post-translational modification of histone tails by methylation (Me), phosphorylation 
(P) or acetylation (Ac) can alter the higher-order nucleosome structure. Nucleosome 
structure can be regulated by ATP-dependent chromatin remodellers (yellow 
cylinders), and the opposing actions of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). Methyl binding proteins, such as the methyl-CpG-binding 
protein (MECP2), target methylated DNA (yellow) and recruit HDACs. 
 
A. DNA methylation and histone deacetylation induce a closed-chromatin 
configuration and transcriptional repression.  
 
B. Histone acetylation and demethylation of DNA relaxes chromatin, and allows 
transcriptional activation. 
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Cell lines and reagents: 
The mutation status of the human glioma cell lines Hs683, LN229, SF767, LN401, 
U373, U343, LN71, LN18, LN319, LN215 of TP53, p16/p14 and PTEN genes has 
been previously established (Ishii, Maier et al. 1999). HeLa is a human cervix 
carcinoma cell line, MCF-7, HBL, SKBR-3 are human breast cancer cell lines, Calu6 
is a colon cancer cell line. The human embryonic kidney cell line HEK293, the 
human skin fibroblast HSF and the rat aortic smooth muscle cell line RASMC are 
non-cancer cell lines and used as control cell lines for testing cytotoxicity. All the 
previous cell lines were cultured in Eagle medium containing 25mM glucose, 
glutamine, standard antibiotics and 10% FCS, except MCF-7, HBL, SKBR-3, 
cultured in RPMI medium with 25mM glucose, glutamine and standard antibiotics 
and 5% FCS. All cells were maintained at 37°C in 5% CO2. The pharmacological 
inhibitors Glivec, AEE788, RAD001, LAQ824 and EPO906A were kindly provided 
by Novartis-Pharma AG, Basel. The other drugs, namely 2-deoxy-D-glucose (2-DG), 
Trichostatin A (TSA), Sodium Butyrate (NaB), LY294002 (LY) and Indomethacin 
(IND) as well as Pyruvate, Oligomycin, Cycloheximide (CHX) and Sodium Azide 
(SA) were purchased from Sigma.  
 
Western analysis and Antibodies: 
After drug treatment, cells were washed with 1xPBS, scrapped in cold SDS lysis 
buffer containing 2% sodium dodecyl sulfate (SDS), 50mM Tris pH 6.8, 0.1M DTT, 
boiled and frozen at –20°C. For the analysis of apoptotic and signal transduction 
markers, protein lysates were separated by size on denaturing SDS-polyacrylamide 
gels (SDS-PAGE) ranging from 8 to 13% depending on the molecular weight to be 
resolved and transferred to nitrocellulose membranes (Hybond, ECL, Amersham 
Biosciences). Membranes were probed with the following primary antibodies: Akt 
antibody (kindly provided by Dr Brian Hemmings, FMI Basel), Mouse anti-S6 
(kindly provided by Dr George Thomas, FMI, Basel), phospho-RB (Ser 807-811), 
phospho-S6 (Ser-240/244), S6K and phospho-S6K (Ser-389), phospho-Akt (Ser-473), 
AMPK and phospho-AMPK-α (Thr-172), PARP antibodies provided by Cell 
Signaling (Beverly, MA). Total RB and cytochrome c antibodies were provided by 
BD pharmingen. p21, Cyclin A, ERK (p42 and p44) and phospho-ERK (Tyr 204 of 
p42 and p44) antibodies were obtained by Santa Cruz Biotechnology, (Santa Cruz, 
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California). Rad51 was purchased from Upstate Biotechnology (Inc, Lake Placid, 
NY). Decorated proteins were revealed using Horseradish peroxidase-conjugated 
anti-mouse or anti-rabbit immunoglobulins (obtained from New England Biolabs, 
Beverly, MA) visualized by chemiluminescence (ECL: Amersham Biosciences).  
 
 Cell Viability Assay: 
DNA content and apoptosis were monitored by FACS analysis on a FACSCalibur 
(Becton Dickinson) and statistics were determined with Cell Quest software. All cell 
lines were seeded at a same density during 48h and treated with the drugs during 72h 
or the indicated time. The cells were trypsinized and fixed in 70% ice cold ethanol 
during 1h, stained with 50µg/ml propidium iodide for FACS analysis. The percentage 
of dead cells was determined by the content of cells in pro-G1. The percentage 
resulted from three independent experiments. The results show the average value and 
standard deviation resulting from three independent experiments. 
 
Proliferation determination by BrdU incorporation  
Cells were treated with various drugs in fresh medium during the indicated time. 
10µM bromodeoxyuridine (BrdU) was added 30 minutes before the end of the 
treatment and cells were labelled with an anti-BrdU with DNAse kit (Becton 
Dickinson, Pharmingen, San Diego, CA) according to the manufacturers’ 
recommendations and 1µg/ml PI. Combined detection of BrdU incorporation and 
DNA content using PI was performed using FACS. Proliferating cells are BrdU 
positive and detected under FL-1 and FL-2 channels (FL = fluorescence). Results 
show the average value and standard deviation resulting from three independent 
experiments. 
 
Cell migration assay. 
LN229 cells were plated at 70% confluence in the normal DMEM in 6-well dishes. 
48h after seeding, the monolayers were wounded by scoring with a sterile plastic 
200ml micropipette tip in the middle of the wells, washed with 1X PBS and fed with 
normal DMEM or normal DMEM containing 2-DG or RAD001. After 36h, cells were 
fixed in 70% ice-cold ethanol during 1h at 4°C and photographed using a high and 
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low-magnification phase-contrast microscope. The extent of migration into the wound 
area was evaluated qualitatively. 
Colony Forming Assay: CFA 
One thousand cells were plated in 6 cm dishes and grown for 72 hours in normal 
medium. 2-DG or RAD001 were then added for an additional 72h. Cells form 
colonies of various sizes. Cells were washed in 1X PBS and fixed with ice cold 70% 
ethanol for 1h. Plates were washed once more and fixed cells were stained with 
Giemsa for 5 to 20 minutes. Plates were washed with H2O until only cell colonies 
remain colored. The number of colonies was determined using a “colony counter”. 
Colony size is defined and colonies >50 µm diamteter were counted. The histograms 
show the average value and standard deviation resulting from three independent 
experiments. 
 
Apoptosis assessment by Annexin-V staining 
LN401 were seeded and cultured for 48h in normal DMEM exposed to 25mM 2-DG 
and/or 20nM RAD001 during 72h. Dead and viable cells were pooled and stained 
with 1µg/ml PI and Annexin-V (Annexin V-FITC, BD Pharmingen, San Diego, CA). 
according to the instructions of the manufacturer. Cells were incubated at room 
temperature for 15 min and analyzed by flow cytometry. Annexin-V binds to those 
cells that present phosphatidylserine on the outer layer of the cell membrane, and 
propidium iodide stains the cellular DNA of those cells with a compromised cell 
membrane. This allows the discrimination between live cells (unstained with either 
fluorochrome), apoptotic cells (stained only with Annexin V) and necrotic cells 
(stained with both Annexin V and Pi). Dead cells are propidium iodide and/or 
Annexin-V positive. 
 
Measurement of cytochrome c release. 
LN229, SF767, Hs683, LN401, U373 and U343 cell lines were cultured in glucose 
free medium during the indicated times, floating and attached cells harvested by 
trypsinization were pooled and slowly centrifuged at less than 600 rpm. Cells were 
gently lysed for 2 minutes in an ice-cold buffer containing: 250 mM sucrose, 1 mM 
EDTA, 0.1% digitonin, 25 mM Tris, pH 6.8. Lysates were centrifuged for 2 minutes 
at 12,000g, supernatants and pellets were adjusted on same volumes and mixed with 
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6xSDS sample buffer before loading on a 15% SDS-PAGE gel. Polypeptides were 
transferred to nitrocellulose membranes (0.2 µm; Schleicher & Schuell, Keene, NH), 
and cytochrome c was detected by immunoblotting with a monoclonal antibody 
purchased from Pharmingen, San Diego, CA. 
 
ATP measurement:  
Hs683 cells cultured in 6-well dishes were treated with 25mM 2DG and 60nM 
LAQ824. The ATP levels were measured using a luciferase-based assay kit (ATP 
Bioluminescence Assay Kit CLS II, Roche). Cells were lysed by a cell lysis buffer, 
incubated at room temperature for 5 min, before the measurement of luciferase 
activity. For each well, ATP levels were normalized by comparison to the amount of 
total protein by the Bio-Rad protein assay reagent. The measurement show the 
average value and standard deviation resulting from three independent experiments. 
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ABBREVIATIONS 
 
2-DG: 2-deoxy-D-glucose 
4EBP-1: 4E binding protein-1 
 
 
AMP: adenosine mono-phosphate 
AMPK: 5’AMP-activated protein kinase 
ARF: p14 
ATP: adenosine tri-phosphate 
 
BBB : blood-brain barrier  
BrdU: bromodeoxy-uridine 
 
CDK: cyclin dependent kinase 
CHX: cycloheximide  
CNS: central nervous system 
CSF: cerebrospinal-fluid 
 
EC50: 50% effective concentration 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
ERK1/2: extracellular regulated-signal kinase 1 and 2 
 
FAK: focal adhesion kinase  
FDG: fluorodeoxyglucose 
FKBP12: Immunophilin FK506 binding protein (FKBP12)  
 
GBM: glioblastoma multiforme 
GIST: gastrointestinal stromal tumor 
GLUT: glucose transporter 
GlcNAc: N-acetylglucosamine  
 
HDM2: human double minute 2 
HDAC: histone deacetylase 
HDIs: histone deacetylase inhibitors 
HIF-1: hypoxia inducible factor-1  
 
IC50 : concentration where 50% of apoptosis is reached 
IGFR-I: insulin-like growth factor receptor-1 
IGF1: insulin growth factor 1 
 
PDGF: platelet-derived growth factor 
PDGFR: platelet-derived growth factor receptor 
 
MDM2: mouse double minute 2 
mTOR: mammalian target of rapamycin 
NSCLC: non-small-cell lung cancer 
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O-GlcNAc: O-linked--N-acetylglucosamine  
 
PDGF: platelet-derived growth factor 
PDGFR: platelet-derived growth factor receptor 
PET: positron-emission tomography 
Pgp: P-glycoprotein 
PI3K: phosphatidil inositol (3,4,5) kinase 
PI2P: phosphatidylinositol(3,4)-biphosphate 
PI3P: phosphatidylinositol(3,4,5)-triphosphate  
PKI: protein kinase inhibitor 
PTEN: phospatase tensin homolog 
 
RB: retinoblastoma  
RTK: receptor tyrosine kinase 
RTKi: receptor tyrosine kinase inhibitor 
 
S6: Small ribosomal protein 6 
S6K: Small ribosomal protein 6 kinase 
SA: Sodium Azide 
SAHA: suberoylanilide hydroxamic acid 
SBHA: suberic bishydroxamic acid  
SCF: stem cell factor 
SiRNA: small interfering RNAs 
 
TGFβ: tumor necrosis factor  
TSC1/2:Tuberous Sclerosis Complex  
 
VEGF: vascular endothelial growth factor 
VEGFR: vascular endothelial growth factor receptor 
 
WHO: world health organization 
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Figure 1:  AEE788 inhibits EGF-dependent activation of EGFR and induces apoptosis in 
human glioma cell lines
(A) Western analysis using various antibodies described in Materials and Methods. Effect of 
AEE788 on EGFR and FAK phosphorylation in LN229 human glioma cell line. EGF was 
added for 10 minutes (B) FACS analysis: effect of AEE788 on cell cycle profile, after 36h 
incubation with 1µM AEE788 , repartition of cells in each phase G1 or G2/M of the cell cycle.  
(C) AEE788 titration: effect of AEE788 on the survival of human glioma cell lines, after 4 days 
treatment. Cell lines were grouped according to their response to the drug.
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Figure 2. Glivec induces weakly apoptosis in human glioma cell lines.
Glioma cell lines were treated for 4 days with increasing doses of glivec then cell 
survival was measured by FACS as described in Materials and Methods
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Figure 3 : RAD001 has only a cytostatic effect on human glioma cell lines.
(A) RAD001 IC50 titration: effect of RAD001 on the proliferation of PTENwt and PTEN 
mutant human glioma cell lines. (data from Heidi Lane , Novartis, Basel). (B) cytostatic effect: 
four glioma cell lines were treated with 20nM RAD001 for 72h, G1 accumulation of cells in the 
presence of the drug was compared with the % of cells in G1 under untreated condition. (C) 
LN229 cell lines was treated with RAD001 for 72h or 5days and western analysis was performed 
to determine phosphorylation and total protein levels of RB and S6 (D) Effect of increasing doses 
of RAD001 (20, 200, 2000) on survival of human glioma cell lines (LN401, LN229, U373, 
SF767) after 5 days exposure to the drug. Apoptosis was determined by FACS after PI staining. 
The initial basal levels of apoptosis were set to 1.
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Figure 4. Combinatorial effects of specific inhibitors: RAD001,AEE788 and Glivec on 
human glioma cell survival
All drugs were added simultaneously for 4 days and cell survival was determined by FACS  
as described in Materials and Methods. (A) Response type 1: Resistance to apoptosis,  
RAD001 reduces basal levels of apoptosis. (B) Response type 2: Weak cell death induced 
by AEE788 and Glivec. (C) Response type 3: AEE788 and/or Glivec induce apoptosis. 
RAD001 enhances apotposis induced by AEE788 in LN215 (1) or reduces the cytotoxic 
effect induced by AEE788 and Glivec in SF767 (2).
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Figure 5. Cytostatic effect by drug combinations of RAD001, AEE788 and Glivec on 
human glioma cell growth. 
SF767 (A) and Hs683 (B) cell lines were treated by the indicated drug combinations 
performing a colony formation assay (CFA) in which number of colonies were determined 
after 72h. Details of the CFA are described under Materials and Methods
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Figure 6. Table summarizing the effects of AEE788, Glivec and RAD001 observed on 
the survival of 10 glioma cell lines upon single or combined application. No 
correlation between cell death and the genetic background was observed.
PT
EN
p5
3
p1
6/
p1
4
U
34
3
W
T
de
l
m
ut
U
37
3
W
T
m
ut
m
ut
LN
22
9
W
T
de
l
m
ut
LN
40
1
de
l
m
ut
m
ut
LN
71
de
l
m
ut
m
ut
LN
31
9
W
T
m
ut
m
ut
    genetic
background
A
EE
78
8
G
liv
ec
R
A
D
00
1
Single drug
>1 >1
>1
>1
>1
>1 >1
>1
10 10
10
10
-
-
-
-
-
-
A 
+ 
G
A 
+ 
R
R 
+ 
G
Combination
-
-
-
-
- -
-
--
-
-
-
- -
- -
A+
R+
G
-
-
-
-
- -
- -
H
s6
83
W
T
de
l
m
ut >1 >1 - - -- - --
-
-
-
>0
.5
SF
76
7
W
T
W
T
W
T 0.
1 - -++ ++++
Ty
pe
 3
>0
.5
LN
18
W
T
W
T
de
l
>1 - -- -+
Ty
pe
 2
Ty
pe
 1
LN
21
5
W
T
m
ut
m
ut
>0
.5
>0
.5 - ++++++ +
-
-
Figure 7. Specific cytotoxicity of LAQ824 and EPO906A on cancer cell lines compared 
to non-cancer cell lines. 
(A) Titration of LAQ824: effect of LAQ824 on survival of human glioma and HEK293 cell 
lines. Cell survival was analysed by FACS as described in Materials and Methods (B) The 
various cell lines were treated with  60 nM LAQ824 for 72h and loss of viability was 
determined by FACS. (C) Various cell lines were treated with 30 nM LAQ824 for 48h and 
proliferation was determined by BrdU incorporation (NT=non treated) (D) Increasing doses 
of  EPO906A were applied to human cell lines for 72h as in A and survival was determined 
by FACS.
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Figure 8. Effect of the combinations of indomethacin (IND) and LAQ824 on the 
survival of six glioma cell lines. 
Hs683, LN401, LN229, U373, SF767 and U343 glioma cell lines were treated with 
increasing doses of LAQ824 (10, 30, 60, 90, 180nM), with or without 50µM IND during 
72h and cell survival was determined by FACS as described in Materials and Methods
Figure 9. Effect of the combinations of indomethacin (IND) and LAQ824 on protein 
levels and on the survival of other cancer cell lines (Calu-6, MCF-7) . 
(A) Hs683 was treated for 24h with 60nM LAQ824, 50µM indomethacin (IND) or a 
combination of both drugs. Cell extracts were done after 24h treatment and protein 
samples were loaded on a SDS-gel. Protein levels were determined by Western-Blot (B) 
The colon cancer cell line Calu-6 and the breast cancer cell line MCF-7 were cultured in 
triplicates in standard medium during 48h. Cells got fresh medium before to be treated 
with increasing doses of LAQ824 (10, 30, 60, 90, 180nM), and/or 50µM IND during 72h 
after which time floating and viable cells were pooled and cell death was measured using 
FACS analysis (pro-G1 phase) as described under „material and methods“
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Figure 10. Effect of the combinations of indomethacin (IND) and LAQ824 on the 
survival of non-cancer cell lines. 
HEK293, HSF and RASCM cell lines were cultured in triplicates in standard medium during 
48h. Cells got fresh medium before to be treated with increasing doses of LAQ824 (10, 30, 
60, 90, 180nM), and/or 50µM IND during 72h after which time floating and viable cells were 
pooled and cell death was measured using FACS analysis (pro-G1 phase) as described under 
„material and methods“ (A) Human embryonic kidney cell line (B) Human Skin Fibroblast 
cell line (C) Rat aortic smooth muscle cell line
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Figure 11: 2-DG treatment and glucose withdrawal induce apoptosis in glioma cell 
lines
(A) Various cell lines were treated with increasing doses of 2-DG for 48h and proliferation was 
determined after by BrdU staining and FACS analysis as described in Materials and Methods. 
BrdU incorporation in the non teated cells was set to 100%. (B) Various cell lines were treated 
with increasing doses of 2-DG for 72h and cell survival was determined by FACS (HSF: 
human skin fibroblast, RASMC: rat aortis smooth muscle cell, HEK: human embryonic 
kidney, HeLa: cervix, MCF-7: breast, Calu-6: colon). (C) Glioma cell lines and HeLa cell line 
were treated with glucose-free medium (-glc) and cell survival was determined after the 
indicated times. Cytochrome c release was measured after 24h under glucose starvation (CE: 
cytoplasmic extract, P:pellet) as described in Materials and Methods. 
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Figure 12: Effect of 2-DG on glioma cell proliferation markers AKT and S6 and on 
the apoptosis markers Rad51 and PARP.
(A) Phosphorylation and total protein levels of AKT and S6 were determined by Western 
analysis at the indicated times after the exposure of the glioma cell lines to 100mM 2-DG 
(B) Rad51protein levels and PARP cleavage were determined by Western analysis at the 
indicated time after the exposure of the cells to 100mM 2-DG.The antibodies used are 
described in Materials and Methods.
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Figure 13: 2-DG and glucose withdrawal reduce ATP levels in a two-phase manner . 
Pyruvate does not rescue cell survival upon  2-DG or glucose withdrawal.
(A) U373 cell line was treated with increasing doses of 2-DG and glucose withdrawal (Glc wd) 
and  ATP levels were measured 1h, 8h, 24h and 48h after the beginning of the treatment, as 
described in Materials and Methods. (B) U373 cell line was treated with 25mM 2-DG and the 
phosphrylation levels of AMPK was determined by Western analysis after the indicated 
times. (C) Glioma cell lines were exposed to the indicated treatments, and cell death was 
determined by FACS after 72h (4.5g/L pyruvate, 25mM 2-DG) 
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Figure 14: 2-DG reduces more strongly proliferation, colony formation and 
migration of glioma cell lines than RAD001
(A) BrdU staining: effect of 5mM 2-DG and/or 20nM RAD001 on the proliferation of 
four glioma cell lines, after 48h exposure. BrdU was added for 1h before the end of the 
treatment. BrdU incorporation in the non teated cells was set to 100%. (B) LN229  cell 
line was submitted to Colony Formation Assay for 72h in presence of 1 or 5mM 2-DG or 
20nM RAD001 (RAD) or a combination of both drugs. The number of colonies > 50µm 
was determinated by a colony counter instrument. (C) Migration assay: wound healing 
assay. LN229 was subjected to migration in presence of 2-DG or RAD001 at the 
indicated concentrations, for 72h. (RAD001 was added 24h before the wound was made). 
(MF: magnification)
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Figure 15: RAD001 decreases 2-DG-induced apoptosis in glioma cell lines
(A) LN229, SF767, U373 and LN401 cell lines are treated with the indicated drugs for 
72h and cell survival was determined by FACS. (B) LN401 was exposed to the indicated 
drugs for 72h and apoptosis was determined by Annexin-V staining as descibed in 
Materials and Methods. (C)  LN401 was exposed to the indicated drugs for the indicated 
times and PARP cleavage was analysed by Western. (D) LN401 was submitted to 
increasing doses of 2-DG or to the combination of 2-DG and RAD001 for 72h. Cell 
surival was determined by FACS. 20nM RAD001 was used for all treatments.
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Figure 16: 2-DG is dominant over RAD001 for inhibiting cell proliferation
(A) LN401were exposed to increasing doses of 2-DG in presence or not of 20nM RAD001 
for 72h. At the end of the experiment, floating and attached cells were counted. (B)  LN401 
was exposed to 25mM 2-DG, 20nM RAD001 or both drugs for 36h and cell cycle profiles 
were determined by FACS after Pi staining. The percentages of cells in each phase are 
indicated on the histogramms (C) Cyclin A levels were followed for 72h after 25mM 2-
DG or 20nM RAD001 treatment by Western analysis. Equal amounts of protein were 
loaded. (RAD: RAD001)
 Time (h) 
Figure 17 : Effect of 2-DG and RAD001 on the phosphorylation of AKT, ERK and S6.
(A) LN229 cells were treated for 8h with 20nM RAD001, 25mM 2-DG or the combination 
of both drugs and the phosphorylation of AKT (Ser 473), ERK(1/2) (p42/p44), and S6 (Ser 
240/244) protein were determined by Western analysis as described in Materials and 
Methods. (B) U373 cell line was treated as in (A)
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Figure 18 : RAD001 delays apoptosis induced by glucose withdrawal
Glioma cell lines were submitted to glucose starvation (- Glc), in presence or in absence of 
20nM RAD001 (RAD) during the indicated times and cell death was measured by FACS 
as described in Material and Methods.
Figure 19 : Effect of LY294002, RAD001 and 2-DG on the survival of LN401 cell line
(A) LN401 was exposed to the PI3K inhibitor LY294002 (LY) and the phosphorylation 
levels of AKT were followed by Western analysis at the indicated times. (B) LN401 was 
treated with single or various drug combinations (25mM 2-DG, 20nM RAD001 and 20µM 
LY) for 72h and cell viability was determined by FACS. LY was added every 16h. Cell 
death is measured by FACS. (RAD: RAD001) 
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Figure 20. Effect of the combinations of 2-deoxy-D-glucose (2-DG) and HDACs 
inhibitors (HDIs) on the survival of the glioma cell lines Hs683 and cervix 
carcinoma cell lines HeLa. 
(A) Hs683 and HeLa cells were treated with 25mM 2-DG and/or increasing doses of 
sodium butyrate (NaB) for 72h. Cell death was measured by FACS analysis after PI 
staining. (B) The same cell lines were treated with 25mM 2-DG and/or increasing doses 
of trichostatin A (TSA) for 48h. Cell death was measured as previously (C) Hs683 and 
HeLa cells were treated with 25mM 2-DG and/or TSA (100nM) or NaB (10mM) for 
8h and  p21 protein and actin levels were determined by Western analysis. 
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Figure 21. Effect of the combinations of 2-deoxy-D-glucose (2-DG) and LAQ824 
on the survival of six glioma cell lines. 
Hs683, LN401, LN229, U373, SF767 and U343 glioma cell lines were cultured in 
triplicates in standard medium during 48h. Cells got fresh medium before to be treated 
with increasing doses of LAQ824 (10, 30, 60, 90, 180nM), and/or 25mM 2-DG (only 
SF767 was treated with 5mM 2-DG) during 72h after which time floating and viable 
cells were pooled and cell death was measured using FACS analysis (pro-G1 phase) as 
described under “Experimental Procedures”.
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Figure 22. The synergistic induction of apoptosis is 2-DG and LAQ824 dose-
dependent and induces PARP cleavage.
(A) Hs683 was treated with increasing concentrations of LAQ824 (10, 30, 60, 90, 180nM) 
and of 2-DG (1, 5, 25mM) for 72h cell death was measured by FACS. (B) Hs683 was 
treated with 25mM 2-DG and 60nM LAQ824 for 72h and cell survival was determined at 
the indicated time points by FACS.(C) HS683 was treated with 60nM LAQ824 and/or 
25mM 2-DG for 72h and the cell cycle profile was established by FACS as described in 
Materials and Methods. M1 gives the percentage of cells in the pro-G1 phase. (D)  Hs683 
was exposed to 60nM LAQ824 and/or 25mM 2-DG, SDS samples were prepared at the 
indicated time points and submitted to SDS-Page. The cleavage of PARP was assessed by 
immunoblotting with anti-PARP. (PARP cleavage is defined by the appearance of the 86 
kDa band.)
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Figure 23. Dominance of 2-DG over LAQ824 on the inhibition of Hs683 
proliferation.
(A) Hs683 was exposed to increasing doses of LAQ824 (10, 30, 60, 90, 180nM) and/or 
2-DG (1, 5, 25mM), the total number of cells was determined after 72h treatment, by 
pooling attached and floating cells and counting total number of cells. (B) The cell cycle 
profile of Hs683 was determined by FACS after 16h treatment with 25mM 2-DG 
and/or 60nM LAQ824. Percentages of cells in G1, S and G2/M phases are represented 
on the histograms. (C) Hs683 was exposed to 25mM 2-DG or 60nM LAQ for the 
indicated time, equal amounts of protein were submitted to Western analysis to 
determine cyclin A protein levels.
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Fig. 24. Effect of 2-DG, LAQ824 and the combination on AKT, ERK and Rad51 
proteins .
(A) Hs683 was exposed to 25mM 2-DG and/or 60nM LAQ824, cells were lysed at 
the indicated time and equal protein amounts were applied to Western analysis to 
determine the phosphorylated levels of Akt (B) Same protein samples as in (A) were 
applied to Western analysis to determine the phosphorylated levels of ERK protein 
and (C) for the total levels of Rad51 protein, as descibed in Materials and Methods.
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Fig. 25. Effect of 2-DG and LAQ824 on ATP levels and on the proteins involved in the 
energy regulatory pathway.
(A) Hs683 cells were incubated in the presence of 25mM 2-DG and/or 60nM LAQ824 
(LAQ). At the indicated time points, ATP levels were determined as described upon Materials 
and Methods. ATP levels of the untreated cells at time t=0 were set to 100%. (B) Hs683 was 
exposed to the same treatment as in (A) and protein samples were made at the indicated time 
points. Equal amounts of protein were applied to Western analysis to determine the 
phosphorylated form of AMPK (AMPK-P) and (C) S6 (S6-P).
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Fig. 26. p21 plays a major role in the synergistic induction of apoptosis.
(A) Hs683 cells were exposed to 25mM 2-DG and/or 60nM LAQ824 for 2, 4, 8 and 24h, 
and p21 protein levels were determined by Western analysis as described in Materials and 
Methods. (B) SF767, LN229, U343, U373 and LN401 were treated with 25mM 2-DG 
and/or 60nM LAQ824 for 8h and p21 protein cell content was determined by Western 
analysis as in (A). (C) Western analysis of p21 and actin proteins after 24h exposure of 
Hs683 to increasing doses of LAQ824, in  combination or not with 25mM 2-DG. (D) Hs683 
was treated with  500nM LAQ824, 25mM 2-DG or the combination of both drugs and cell 
death was measured by FACS analysis. (E) Hs683 was treated with increasing amounts of 2-
DG (1, 5, 7.5, 25) for 8h in presence of not of 60nM LAQ824 and p21 protein levels were 
determined by Western analysis as in (A). 
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Fig. 27. Effect of the sequential addition of LAQ824 or 2-DG on the cell survival of 
Hs683.
(A) Hs683 was exposed to 60nM LAQ824 and p21 protein levels were determined at the 
indicated times by Western analysis. (B) Hs683 was treated with 60nM LAQ at time=0 
and 25mM 2-DG was added  simultaneously or after LAQ824 at the indicated times. For 
each sequential addition, cell death was measured after 72h treatment in the presence of 
both drugs, by FACS (C)  The sequential addition was realized in the same way as in (B), 
but 2-DG was added first or before LAQ824 at the indicated times. Cell death was 
determined by FACS.
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Fig. 28. The synergistic induction of apoptosis in Hs683 cell line is not extensively 
linked with energy levels.
(A) HS683 were treated with 4.5g/L (25mM) 2-DG and 60nM LAQ824 in presence or 
not of 4.5g/L pyruvate. Cell death was measure by FACS after 72h exposure to the 
compounds. (B) HS683 was exposed to 1µM oligomycin (O) in combination or not   
with 60nM LAQ824 for 72h and apoptosis was determined FACS. Analysis of p21 and 
actin proteins was done by Western after 8h exposure to the drugs. (C)  Hs683 was 
incubated in glucose-free medium (-glc) in presence of not of 60nM LAQ824 (L) for 36h 
and cell death was determined by FACS. (D) Hs683 was treated with 200nM RAD001, 
60 nM LAQ824 or the combination for 72h and cell survival was measured by FACS. 
The levels of p21, Actin and phosphorylation of S6 were determined by Western 
analysis after 24h exposure of Hs683 to 200nM RAD001, 60nM LAQ824 or both 
drugs.
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Fig. 29. The combination of HDIs and 2-DG induces synergistically apoptosis in other 
cancer cell lines.
(A) HeLa cell line was exposed to 25mM 2-DG and 60nM for 72h. Cell death was measured by 
FACS after Pi staining. (B) Phosphorylation and total levels of S6, p21 and Actin were 
determined by Western analysis after 12h exposure to 60nM LAQ, 25mM 2-DG or the 
combination of drugs. (C) Increasing doses of LAQ824 (10, 30, 60 and 90nM) and 5 or 25mM 2-
DG were applied to SKBR-3 cell line and cell survival was determined by FACS after 72h (D) 
MCF-7 was treated as in (C),doses of  LAQ824: 10, 30, 60, 90, 180nM (E) HBL was treated as 
in (D).
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Fig. 30. The combination of HDIs and 2-DG does not induce apoptosis in non-
cancer cell line HEK293, RASMC, except in  HSF.
(A) HEK293 cell line was exposed to 25mM 2-DG and increasing amounts of LAQ824 
(10, 30, 60, 90, 180nM) for 72h and cell death was measure by FACS after Pi staining. 
(B) HEK293 cells were exposed to increasing doses of 2-DG or LAQ824 for 72h and the 
total number of cells was determined. (C) The rat aortic smooth muscle cells (RASMC) 
were exposed to increasing doses of LAQ824 (10, 30, 60, 90, 180nM) and 25mM 2-DG 
for 72h and cell survival was determined by FACS (D) The human skin fibroblasts (HSF) 
was treated as in (C) and cell survival was determined by FACS.
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Figure 31: Model of the synergistic induction of apoptosis in cells by HDAC inhibitors 
and 2-DG
(A) HDACs inhibitors (HDIs) are inducing reexpression of certain genes like p21, that regulate 
cell cycle progression through G1 phase and protect cells against apoptotic signals by blocking 
caspase-3 activation. In addition, HDIs allow reexpression of pro-apoptotic proteins that induce 
apotposis via the mitochondria, like Bcl-2  or via the death receptors pathways, like Trail.
(B) In presence of the glycolytic inhibitor, the re-expression of p21 by HDACs inhibitors is 
abrogated via inhibition of transcription (by altering glycosylatio of the transcription factor Sp1) 
that leads to a strong  induction of apoptosis, via the mitochondrial or death receptor pathways. 
Inhibition of translation might also be involved in the decrease of p21 levels. In addition, 2-DG 
induces apoptosis via cytochrome c release.
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Basel (Switzerland), co-direction with University of Strasbourg (France).  
 
Objective: rationally combine drugs for the treatment of human glioblastoma multiforme (GBM). 
                Testing new treatments (new biological, cytotoxic and cytostatic drugs in preclinical development) in  
GBM cell lines: 
-Human glioma signaling pathways: impact of PI3K/Akt/mTOR axe (EGFR, VEGFR, PDGFR) and the  
energy pathway in cancer treatment, mechanisms of apoptosis. In collaboration with FMI, Basel.  
-In vitro drug screening. In collaboration with Novartis-Pharma, Basel. 
 
 
 
 
 
 
                     
2001       Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC, Illkirch, France)  
                                  
Post graduate diploma in Molecular and Cellular Biology, directed by Prof Pierre Chambon, under the 
supervision of Dr Johan Auwerx and Dr Lluis Fajas. 
  
Characterization of an important role of PPARgamma in cell cycle control and adipocyte differentiation 
through cross-talk with E2F and RB signaling pathways. 
                                                           
2000       Université Louis Pasteur (ULP), (Strasbourg, France)  
 
Master’s degree in Biochemistry  
 
TRAININGS 
 
2009  • Autumn Introductory Course - TOPRA  (Prague, Czech Republic) 
  • e-CTD 
 
2008  Seminar on Biosimilars - SWISS BIOTECH ASSOCIATION (Bern, Switzerland) 
 
2007  • Excel Level 2 
• German (Supercomm  Geneva, Switzerland) 
  • Colorectal cancer  
               
2005 Introduction in Regulatory Affairs, Pharmacovigilance – Swiss and european pharmaceutical 
regulatory system, MARAS AG, (Cham, Switzerland).  
 
2002 - 2005 Courses in cancer development and cancer treatments. (Biozentrum Basel, Switzerland)  
 
 
PUBLICATIONS 
 
Egler V, Korur S, Failly M, Boulay JL, Imber R, Lino M M and Merlo A.  Histone deacetylase inhibition and 
blockade of the glycolytic pathway synergistically induce cancer cell death. Clinical Cancer Research. 2008 May 
15;14(10):3132-40. 
 
Failly M, Korur S, Egler V, Boulay JL, Lino MM, Imber R, Merlo A.. Combination of sublethal concentrations of 
epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol 
Cancer Ther. 2007 Feb;6(2):773-81.  
 
Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARgamma controls cell proliferation and 
apoptosis in an RB-dependent manner. Oncogene. 2003 Jul 3;22(27):4186-93 
 
Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J. The retinoblastoma-histone 
deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell. 2002 Dec;3(6):903-10. 
 
 
COMMUNICATIONS  
 
- 3rd Regional Oncology Symposium Landgut Castelen, Augst, Switzerland, May 2003. (oral) 
- Forschungstag 2003, Departemente Chirurgie und Aneasthesie, Basel, August 2003. (oral) 
- Neurex Symposium, Biozentrum, Basel, Switzerland, June 2003 
- Keystone Symposium, Lake Tahoe (USA), February 2004 (Poster) 
 
 
 
 
 
 
 
ADDITIONAL QUALIFICATIONS 
 
- IT skills:  Microsoft Word, Excel, Photoshop, Powerpoint and general knowledge of PC and Mac   
                               functions. 
Specific skills: MisAMM  data base 
 
- Languages:  French: mother tongue 
             English: fluent 
              German: level B2 (DFDB) 
 
- Driving license since 1995 
 
 
